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The human telomerase reverse transcriptase (hTERT) is the catalytic subunit of the 
telomerase holoenzyme which is critical for the maintenance of telomere lengths and 
the enhanced replicative capacity of the cells. Being silenced during embryonic 
differentiation in normal cells, its reactivation in over 85% of cancer cells has made 
hTERT an attractive therapeutic target in the field of cancer. However in recent years 
there has been accumulating evidence to suggest that hTERT may play a role in cells 
that deviates from its conventional functions of telomere maintenance and 
immortalization. In this light, several studies have shown that expression of hTERT 
can confer resistance against apoptotic triggers and oxidative stress. As such, this 
study originated with the aim of establishing how hTERT can be modulated by ROS 
and more critically if hTERT can modulate the intracellular redox status thus 
bestowing survival advantages onto the cells.  
In this regard, this thesis provides evidence to show that hTERT expression can 
significantly reduce the basal intracellular ROS levels and antagonize the increase in 
cellular ROS levels in response to both exogenous (hydrogen peroxide [H2O2]) and 
endogenous (C1) ROS triggers. Indeed both the transient and stable expression of 
hTERT abrogated the surge in cellular ROS levels following treatment with H2O2 and 
a ROS inducing drug C1. In addition, hTERT silencing potentiated the increase in 
cellular ROS levels following exposure to oxidative stress. The discovery of this non 
canonical function of hTERT in modulating cellular redox status led onto further 
investigations to unravel the plausible mechanisms by which hTERT expression can 
modulate the ROS levels. In this regard, the assessment of the critical antioxidant 




cellular redox balance have shown that hTERT expression can have significant 
positive impact on key antioxidant defences such as the glutathione system, 
peroxiredoxin activity and Mn SOD expression. In addition it has also shown a role 
for hTERT at the mitochondria in increasing mitochondrial COX activity. In 
unravelling the extensive influence of hTERT expression on cellular redox status, the 
physiological relevance of these findings on cell fate was assessed next. Previous 
findings in the lab has established that H2O2 added exogenously or triggered 
endogenously using C1 is a stimulus for cytosolic acidification, which creates a 
permissive intracellular milieu for death execution. Here, we demonstrate that these 
detrimental effects of ROS on the cells such as cytosolic acidification and the 
subsequent mitochondrial engagement could be antagonized by hTERT expression 
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The progressive transformation of normal human cells to malignant derivatives is a 
complex multi step process which requires dynamic alterations to the genome and 
successful breaching of intracellular checkpoints. The multiplicity of cellular defences 
that are in place to prevent the uncontrolled division and invasion of the cells explains 
why cancer is a rare event during the average human life time. However, when the 
immune response is lost or compromised, it paves the way for the onset of cancer. 
Today, cancer has become one of the leading causes of death in many countries 
including Singapore1. 
Over the last quarter of a century, extensive research in the cancer field has explored 
numerous pathways in cancer progression to elucidate effective measures to target 
these cancer cells.  However there is no single treatment regime that will work for all 
cancers for they are controlled by different regulatory circuits, armed with a variety of 
adaptive responses and localized in unique microenvironments. Thus, improving 
therapeutic efficacy and selectivity and overcoming drug resistance are the major 
goals in developing anti cancer agents today.  
In order to achieve these goals, exploitation of the intrinsic differences between 
normal and cancer cells could be a valuable approach to target cancer cells for cell 
death. One of the glaring differences between normal cells and cancer cells is their 
difference in telomerase expression. Telomerase is is a multi component 
ribonucleoprotein that adds specific DNA repeats (TTAGGG) to the 3' end of DNA 
                                                 




strands in the telomere regions thus playing a crucial role in telomere maintenance. It 
is active in almost all cancer cells but is inactive in most somatic cells with the 
exception of a few, including stem cells and germline cells, thus making it an 
attractive target for cancer therapy.  
2. TELOMERES AND TELOMERASE 
Telomeres are specialized structures that cap and preserve chromosomal integrity by 
protecting the chromosomal ends from degradation, end to end fusions and 
rearrangement (Greider, 1991). They typically consist of tandem GT-rich repeats 
(TTAGGG) in humans with a single stranded 3’ overhang. With every cell division, 
the telomeres shorten by 50 to 200 base pairs and the inability of the cellular 
machinery to replicate the end base pairs is known as the end replication problem 
(Figure 1) (Bollmann, 2008; Richter T, 2007). The successive loss of the end base 
pairs can critically shorten the chromosome, thus activating growth arrest and cellular 
senescence which will be discussed further in the sections below. However, the 
reactivation of the telomerase protein can help to overcome the end replication 
problem via the addition of telomeric repeats at the 3’ ends of the DNA (Figure 2). A 
central question in telomere biology has long been the mechanism by which 
telomerase maintains telomere length In this regard, previous reports have shown that 
the telomerase would preferentially elongate the shortest telomeres in a cell (Bianchi 
and Shore, 2008; Hemann et al., 2001; Ouellette et al., 2000), extending the telomeric 
G-rich strand through a process that is coupled to the synthesis of the complementary 
strand. However, the latest findings by Zhao et al now show that telomerase in human 




 Figure 1: The end replication problem Conventional DNA polymerases synthesize 
DNA in the 5’ to 3’ direction and cannot begin synthesis de novo. Instead they use an 
8–12-base segment of RNA as a primer (red). The leading strand can, in principle, be 
continuously synthesized (green). The lagging strand is synthesized in short, RNA-
primed Okazaki fragments (blue). After extension, the RNA primers are removed and 
the gaps filled in by DNA polymerase priming from upstream DNA 3' ends. Removal 
of the 5'-most RNA primer generates an 8–12-base gap. Failure to fill in this gap leads 
to a small loss of DNA in each round of DNA replication (Vega et al., 2003).  
 
Figure 2: Telomere elongation by telomerase. First, the nucleotides at the extreme 
3' end of the telomeric DNA primer are hybridized onto one end of the RNA template 
within the RNA domain of the telomerase complex. The 11-nucleotide template 
sequence is complementary to that of almost two telomeric repeats (a). The gap at the 
end of the template is then filled in by synthesis at the catalytic site of the enzyme 
(hTERT), using trinucleoside phosphates. In this way, a complete hexanucleotide 




2.1 Telomerase and telomerase regulation 
The telomerase holoenzyme consists of a catalytic protein subunit, human telomerase 
reverse transcriptase (hTERT), the RNA component of the telomerase (hTR) that is 
used as the template by the reveres transcriptase to elongate the telomeric ends, and 
telomerase associated proteins such as TEP1 that play a primary role in maintaining 
the integrity of the telomeres in normal cells (Greider, 1996). Though hTERT and 
hTR are necessary for telomerase activity, it has been shown that telomerase activity 
is highly correlated with hTERT expression and not that of hTR (Counter et al., 
1998). In this regard, the catalytic subunit hTERT has been proposed by several 
studies to be the rate limiting factor for telomerase activity and will be the focus of 
this thesis (Cong et al., 2002; Poole et al., 2001).  
Telomerase is differentially regulated under normal and pathological conditions. 
While in most human somatic cells telomerase activity is extinguished during 
embryonic differentiation, the highly proliferative cells such as stem cells, germ cells, 
activated lymphocytes, haematopoietic progenitor cells, intestinal crypt cells, 
endometrial cells, basal layer of skin cells and cervical keratinocytes display varying 
degrees of telomerase activity (Counter et al., 1995; Hiyama et al., 1995; Kyo et al., 
1999; Yasumoto et al., 1996). Thus, a tight regulation of telomerase and specifically 
hTERT expression is crucial to meet the proliferative demands of certain cell types 
while preventing excessive proliferation of others to protect from pathological 
consequences. Deregulation of telomerase expression has been associated with several 
human diseases such as human dyskeratosis congenita which is a multiple systems 
disease that results from proliferative deficiencies in highly regenerative tissues such 




majority of human tumours seem to depend on the reactivation of the telomerase 
protein to confer cellular immortality. These conditions that arise from the 
deregulation of telomerase shed light on the importance of telomerase regulation in 
normal human growth and development (Artandi, 2006; Blasco, 2005; Tzukerman et 
al., 2002).  
2.1.1 Transcriptional regulation of hTERT 
The differential expression or regulation of the catalytic subunit of telomerase, 
hTERT, can largely modulate telomerase activity in cells since it is a critical limiting 
factor for telomerase activity. hTERT is present as a single gene copy on chromosome 
band 5p15.33, the most distal band on the short arm of chromosome 5p. (Bryce et al., 
2000). While several differentially spliced forms of hTERT have been identified, the 
protein forms of these alternative spliced forms have not been detected in human 
cells. Analysis of the hTERT promoter has shown that it is highly GC-rich. These 
GC-rich regions form large CpG regions around the ATG translation start codon, 
suggesting that methylation may be involved in the regulation of hTERT expression. 
But a site-specific or region-specific methylation pattern correlating with the 
expression of the hTERT gene has not been identified (Dessain et al., 2000), 
suggesting that epigenetic regulation may not be the main mechanism in telomerase 
regulation.  
hTERT transcription is activated by several proteins with the principle one being the 
oncogenic protein c-myc (Casillas et al., 2003; Kyo et al., 2000). It has been shown 
that c-myc can induce the expression of hTERT and hence, telomerase activity in 
normal human mammary cells and primary fibroblasts. Overexpression of c-myc has 




through heterodimer formation with Max proteins at the promoter region of hTERT 
(Xu et al., 2008). E-boxes are DNA sequences which usually lie upstream of a gene in 
a promoter region to which transcription factors can bind and enhance the 
transcription (Chaudhary and Skinner, 1999; Levine and Tjian, 2003) of the 
downstream gene. Mad proteins are antagonists of c-myc and switching from 
Myc/Max binding to Mad/Max binding can decrease the promoter activity of hTERT 
(Lebel et al., 2007). Another critical regulator of hTERT is the p53 protein. p53 
overexpression has been shown to induce transcriptional down regulation of hTERT 
in a variety of cancer cell lines independent of cell cycle arrest or apoptosis (Li et al., 
1999; Poole et al., 2001; Shats et al., 2004). Other critical transcriptional activators 
would include nuclear factor of kappa light polypeptide (NF-κB), promoter specificity 
protein 1 (SP1) and activator protein 1 (AP1) that will be further discussed in the 
sections below (Poole et al., 2001).   
 
Telomerase activity has also been shown to be induced by the human papilloma virus 
16 E6 (Klingelhutz et al., 1996; Oh et al., 2001). And this activation of telomerase 
activity is independent of E6 action on p53 degradation or c-myc induction (Veldman 
et al., 2001). This effect is cell-type specific and has been observed in mammary 
epithelial cells or keratinocytes but not in fibroblasts. Besides oncogenic proteins such 
as c-myc and E6, the telomerase activity can also be increased by steroid hormones 
such as estrogen. The presence of estrogen responsive elements in the promoter 
region of hTERT serves as a binding site for estrogen receptors, specifically the alpha 
form (Cha et al., 2008) and activates hTERT expression in response to estrogenic 
stimulation (Kyo et al., 1999). In addition, estrogen can also activate c-myc 




estrogenic have also been shown to downregulate telomerase activity and have been 
explored for their chemotherapeutic potential (Nakayama et al., 2000; Park et al., 
2005). 
Telomerase repression has also been extensively studied given the promising potential 
of identifying tumour suppressors that could act by downregulating telomerase 
activity. Transfer of individual human chromosomes into carcinomas led to the 
discovery of chromosomes with the potential to repress telomerase activity. Several 
chromosomes such as chromosome 3, 4, 6 and 10 have been identified to contain 
putative genes that function as telomerase inhibitors in telomerase positive cells to 
antagonize telomerase activity and suppress its expression. The effectiveness of each 
of these chromosomes in eliciting anti telomerase function might be cell type 
dependent. (Backsch et al., 2001; Cuthbert et al., 1999; Nishimoto et al., 2001).  
2.1.2 Post translational modifications of hTERT 
Though transcriptional regulation of hTERT is the primary mechanism in controlling 
telomerase activity, post translational modifications have been shown to provide 
alternative avenues for the regulation of telomerase activity. In this context, it has 
been reported that in normal ovarian tissues and uterine leiomyoma, cells have no 
detectable telomerase activity despite expressing both hTR and full length hTERT 
mRNAs (Ulaner et al., 2000). This lack of correlation between hTERT expression and 
telomerase activity has also been noted in peripheral T and B cells, human colon and 
renal tissues and tumours. The discordance was attributed to the difference in post 
translational modification of hTERT (Minamino et al., 2001; Rohde et al., 2000). 
These data imply that even though hTERT expression is essential for telomerase 




and, as such, further post translational modifications might be required in some cell 
types to toggle between the active and inactive states of human telomerase (Franzese 
et al., 2007).  
In this regard, many studies have shown that post translational modification via 
hTERT phosphorylation can regulate telomerase activity (Chang et al., 2006; Jakob et 
al., 2008; Kang et al., 1999; Kimura et al., 2004; Li et al., 1997; Liu et al., 2001). It 
has been shown that telomerase activity can be enhanced via treatment with the 
protein kinase C (PKC) activator phorbol myristate acetate via the phosphorylation of 
hTERT by protein kinase C and this effect could be inhibited by the PKC inhibitor 
bisindolylmaeimide I (Chang et al., 2006). In addition, treatment of breast cancer 
PMC42 cells with phosphatase 2A resulted in an inhibition of telomerase activity 
which could be alleviated by treatment with phosphatase 2A inhibitor, okadoic acid 
(Li et al., 1997).  
Besides phosphorylation, the localization patterns of hTERT have also been reported 
to be of importance in regulating telomerase activity. Since nuclear localization of 
hTERT is essential to confer its role in telomere maintenance, its subcellular 
redistribution can influence the cellular telomerase activity. Interestingly, it has also 
been reported in several studies that hTERT phosphorylation can lead to its 
translocation from the cytoplasm to the nucleus (Liu et al., 2001; Minamino et al., 
2001). In addition, oxidative stress induced nuclear export of telomerase has also been 
shown to lead to the downregulation of telomerase activity (Haendeler et al., 2003; 







2.2 Senescence and Immortalization 
The lack of the telomerase protein has been shown to induce a progressive shortening 
in the telomeric ends eventually leading to chromosomal instability or cellular 
senescence. The dogma that cells in vitro could indefinitely multiply given the correct 
culture milieu was first challenged by Leonard Hayflick’s findings that human 
somatic cells display a finite replicative potential when cultured in vitro that averages 
around 50 population doublings (Hayflick and Moorhead, 1961). He later went on to 
unravel the relationship that existed between the replicative potential of cultured cells 
and the lifespan of the organism from which they were derived (Hayflick, 1973). It 
was then established that beyond a finite number of population doublings, cells 
generally entered a state of irreversible arrest referred to as cellular senescence or 
mortality stage 1 (M1) (Wright et al., 1989). Bodnar et al showed that the limited 
replicative potential was indeed a result of telomere shortening which acted as an 
inbuilt timer to trigger senescence (Bodnar et al., 1998). Forced expression of 
telomerase in these normal human cells allowed cells to continue proliferating in 
comparison to the control populations that showed a significant decrease in telomere 
lengths and cellular senescence. 
Although telomere length and its attrition contribute to senescence, telomere attrition 
is not the only stimulus for replicative senescence. A growing body of evidence 
suggests that oxidative stress can induce or accelerate the onset of replicative 
senescence and this new concept has been referred to as stress-induced replicative 
senescence (Toussaint et al., 2000). Studies have shown that mouse cells which are 
known to have very long telomeres (>20kb) can senesce in standard culture condition 




 Mouse embryonic fibroblasts (MEFs) that are grown at 3% oxygen 
concentration, which is near physiological range, did not senesce as rapidly as those 
cultured at supra physiological concentrations (20%) (Parrinello et al., 2003). Similar 
studies performed in human cells also show that culturing cells in low oxygen 
tensions can help delay the onset of senescence thereby extending their lifespan 
(Packer and Fuehr, 1977; von Zglinicki et al., 1995). These data illustrate that the 
proliferative capacity of cells is strongly impacted by the intracellular redox status. 
Oxidative stress can induce cellular senescence in several ways. Firstly, oxidative 
stress can increase the rate of telomeric attrition. The triple guanine repeats at the 
telomeric ends are prone to oxidative modifications rendering them more susceptible 
to break and enhance the rate of telomere attrition (Henle et al., 1999; Oikawa and 
Kawanishi, 1999).  Saretzki et al showed that targeting mitochondrial reactive oxygen 
species (ROS) using MitoQ, a mitochondria targeted antioxidant, could counteract 
telomere attrition and extend the lifespan of fibroblasts exposed to mild oxidative 
stress (Saretzki et al., 2003). Secondly, oxidative stress-induced premature senescence 
could be a function of a direct suppression of telomerase activity. Thirdly, oxidative 
stress via the induction of DNA damage, such as double strand breaks, can activate 
critical cell cycle sentinels that mediate cellular senescence, such as the tumour 
suppressor proteins p53 and retinoblastoma (Shay et al., 1991a; Wright et al., 1989).  
The activation of these proteins would then lead to the downstream induction of the 
cell cycle regulators p21 and p16 to trigger and maintain senescence/growth arrest 
(Chen et al., 2005; Kim et al., 2009). Thus, any mutations or loss of function (Finlay, 
1992) that occurs in these regulators would allow the cells to bypass or override these 




shortened, a state referred to as “crisis” or mortality stage 2 (M2) where replication 
ceases due to the critical shortening of the telomeres (Allsopp et al., 1995). Following 
crisis, death is imminent unless the cells become immortalized by derepression of the 
telomerase.  
Overcoming crisis is not ruled by a singular event. It requires the activation of the 
telomerase protein coupled with the acquirement of the ability to repair and maintain 
the eroded chromosomal ends (Shay et al., 1991a). The culmination of these events 
that helps to bypass senescence and overcome crisis results in cellular immortalization 
(Shay et al., 1991b). Forced expression of telomerase negative normal cells with 
hTERT has been shown to extend their life span (Bodnar et al., 1998) and this ability 
to indefinitely maintain normal human cells has been suggested to have valuable 
medical and research applications such as the commercial production of valuable 
proteins and in gaining insights into the aging processes which involves telomerase 
(Leung and Pereira-Smith, 2001; Shay and Wright, 2000).  
The physiological relevance of this immortalization process is demonstrated in cancer 
biology. Though immortalization is an essential requisite for oncogenesis, it does not 
equate to oncogenesis.  Transformation of cells to a tumorigenic state also requires the 
deregulation of the cell cycle checkpoints which are tightly regulated and the 
activation or introduction of oncogenic genes/proteins such as the simian virus 40 
large T antigens, adenovirus E1A and c-myc (Rassoulzadegan et al., 1983; Shay et 
al., 1993). Following transformation, if some key regulators such as p53 are still 
functional, then the cells can be targeted for growth arrest and death. To that end, 




context of cancer therapy due to their ability to trigger growth arrest and cap the 
replicative potential of the cancer cells.  
2.3 The non canonical roles of telomerase 
In recent years, roles deviating from the conventional function of cellular 
immortalization, telomerase activity and overcoming cellular senescence have been 
attributed to the hTERT protein. While some of these roles have been keenly 
associated with the catalytic activity of the telomerase, other roles of hTERT have 
been shown to be independent of its telomerase activity. Interestingly, the catalytic 
activity of telomerase has been shown to be essential for the telomerase to perform its 
roles in DNA repair, cell growth and mitochondrial function. For instance, DNA 
repair has been shown to be compromised in the presence of hTERT catalytically 
inactive mutants (Masutomi et al., 2005). In addition, hTERT has also been shown to 
interact with mitochondrial DNA, thus protecting the mitochondrial genome from 
oxidative stress and the cells from apoptosis (Ahmed et al., 2008). 
Another novel role for hTERT is its involvement in modulating cellular 
responses to apoptotic triggers. Indeed, it has been shown that targeting hTERT may 
help sensitize a variety of cancer cells to apoptotic triggers (Bollmann, 2008; Cong 
and Shay, 2008; Sung et al., 2005). Several studies have also shown that the apoptotic 
resistance conferred upon the cells by hTERT is independent of its telomerase 
activity. In this regard, deletion of the telomerase RNA component failed to alter the 
sensitivity of TERT transgenic MEFs that were more resistance then the TERT 
deficient MEFs to staurosporine (STS) treatment. In addition, N-methyl-D-aspartic 
acid (NMDA) induced excitotoxic cell death of primary neurons was also suppressed 




conferred by hTERT, 293T cells transiently overexpressing a C-terminal 
hemagglutinin (HA)-tagged version of human TERT (hTERT-HA) or control vector 
were treated with STS. In these cells, hTERT expression could protect from STS-
induced engagement of mitochondrial events leading to apoptosis. Overexpression of 
hTERT has also been shown to protect cells from 4625 Bcl-2/Bcl-xL bispecific 
antisense oligonucleotide and HA-14 Bcl-2 inhibitor induced oxidative stress 
mediated apoptosis (Del Bufalo et al., 2005). In contrast to this anti-apoptotic role, a 
recent report demonstrated that the localization of hTERT to the mitochondria 
exacerbated ROS-mediated apoptosis and conferred a controversial pro-apoptotic 
function upon hTERT. (Santos et al., 2004; Santos et al., 2006). Taken together, all 
these works have highlighted a novel role for hTERT in modulating ROS mediated 
apoptosis and brings to light a more critical interaction there exists in the cell; the 
association between ROS and hTERT. 
3. REACTIVE OXYGEN SPECIES   
Oxygen (O2) is an essential element for cellular respiration and a key substrate for 
countless oxidative and enzymatic reactions. It moves freely across cellular 
membranes and generates a variety of oxygen derivatives in cells that are collectively 
termed reactive oxygen species (ROS). ROS includes a wide range of ions or small 
molecules that can be broadly divided into oxygen derived radicals and non radicals. 
A free radical has been defined as any species that is capable of independent existence 
and contains one or more unpaired electrons (Halliwell, 1999). Oxygen derived free 
radicals include superoxide anion (O2.-), singlet oxygen, nitric oxide radical (NO.), 




(H2O2) and peroxynitrite (ONOO-). They are generated when the unpaired electrons 
of oxygen undergo electron transfers to form partially reduced oxygen derivatives.  
3.1 Different types of ROS 
Despite being a free radical, O2.- is not very reactive and, due to its charged nature, it 
is highly compartmentalized to its site of production. The dismutation of two O2.- 
radicals leads to the production of H2O2 which, unlike O2.-, can freely move across 
membranes. Monoamine oxidase can convert O2 to H2O2. Xanthine oxidoreductase, 
which comprises of xanthine oxidase and xanthine dehydrogenase, also produce H2O2 
and O2.- while degrading the purine hypoxanthine to uric acid (Berry and Hare, 2004). 
H2O2 is an important intermediate in the production of other more reactive ROS such 
as hypochlorous acid and OH.. OH. is produced via the Fenton reaction which 
involves the reaction of H2O2 with transition metal ions (e.g. Fe2+ and Cu2+) 
(Halliwell, 1999).  
The OH. radical is more potent then any of the other ROS due to its strong reactivity 
with biomolecules, thus resulting in cellular oxidative damage (Betteridge, 2000; 
Halliwell, 1999). NO. radicals are produced by the enzymatic activity of nitric oxide 
synthases (NOS). NO. radicals, like O2.-, do not readily react with biomolecules. 
However, when the intracellular concentrations of NO. and O2.- are high, these two 
molecules can react to produce ONOO- which is a powerful oxidant. The derivatives 
of NO. are termed Reactive Nitrogen Species (RNS) and they can act together with 
ROS to induce nitrosative stress (Brown and Borutaite, 2006; Fridovich, 1978; Zorov 




3.2 Sources of ROS 
In aerobic cells, mitochondrial respiration is one of the major sources of ROS.  In the 
mitochondrial electron transport chain (ETC), there is a sequential transfer of 
electrons (e-) with cytochrome oxidase (COX) being the terminal acceptor which 
reduces bound O2 to water (Kakkar and Singh, 2007). During this process of electron 
transfer, some electrons may leak onto oxygen and lead to the formation of ROS. For 
instance O2.- results from a single electron transfer to O2. As such, it has been 
estimated that at physiological oxygen levels, 1-4% of oxygen might be incompletely 
reduced to O2.- (Betteridge, 2000; Orrenius et al., 2007). The main sites of ROS 
generation in the mitochondria are complex I (NADH coenzyme Q reductase) and 
complex III via the reduction of oxygen through a single electron transfer to yield O2.- 
(Zacks et al., 2005). The membrane that surrounds the nucleus has also been 
identified to contain an ETC, whose function has not yet been elucidated. The leakage 
of electrons at this site can also give rise to O2.- (Halliwell, 1999). 
Another major source of ROS in the cell is at the endoplasmic reticulum (ER). The 
ER contains enzymes like NADPH-cytochrome P450 reductase that catalyze a series 
of reactions to detoxify lipid-soluble drugs and harmful metabolic products. 
Sometimes, the intermediates in the catalytic cycle can be short-circuited to reduce O2 
rather then its appropriate substrates. This leads to the production of O2.-. In addition, 
the direct leakage of electrons from the flavins in NADPH-cytochrome P450 
reductase enzyme onto O2 can also generate O2.- (Halliwell, 1999; Inoue et al., 2003).  
Numerous oxidases and oxygenases present in the cells also act to reduce O2 or 
transfer O2 to the substrates. One such well-studied enzymatic source of ROS is the 




a heterodimeric flavocytochrome (cytochrome b559) consisting two subunits, 
gp91phox and p22phox, four cytosolic proteins, p47phox, p67phox, p40phox, and the 
small guanosine triphosphate (GTP)-binding protein Rac (1 and 2). This complex is 
activated to assemble at the membrane during respiratory or oxidative burst that will 
result in the release of ROS. The NADPH oxidase generates ROS, and specifically 
O2.-, by transferring electrons from NADPH inside the cell across the membrane to 
reduce O2 (Babior, 2004; Umei et al., 1991). This mechanism is critical for the 
immune system and is employed by phagocytes against microbial intruders.  In 
addition, soluble enzymes such as xanthine oxidase, aldehyde oxidase, flavoprotein 
dehydrogenase and tryptophan dioxygenase can also generate ROS during catalytic 
cycling (Freeman and Crapo, 1982).  
3.3 Functions of ROS 
ROS can have a plethora of effects on cells depending on its type and dose. While 
very high doses are known to elicit necrotic effects, very low concentrations of ROS 
such as H2O2 and O2.- have been shown to activate mitogenic responses through 
tyrosine phosphorylation of phosphatases or directly activating growth factor 
receptors (Denu and Tanner, 1998). Intermediate concentrations (< 500µM of H2O2) 
has been shown to trigger apoptosis (Clement and Pervaiz, 1999; Hampton and 
Orrenius, 1997).  
The intracellular redox balance can be perturbed by endogenous or exogenous 
oxidative stress. The detrimental effects of ROS have been studied extensively over 
the years and have been shown to contribute to aging, ischemia reperfusion injury, 
inflammation and diseases such as atherosclerosis and neurodegeneration. At the 




and DNA damage eventually leading to cell death (Linnane et al., 2007; Schmidt et 
al., 1995). Previous work in our lab has also established that an increase in 
intracellular H2O2 can lead to cytosolic acidification which creates a permissive 
intracellular milieu for protease activation and/or Bax conformational change and 
mitochondrial translocation which facilitates death execution (Ahmad et al., 2004; 
Clement et al., 1998; Hirpara et al., 2001).  
At this junction, it is imperative to emphasize that the effects of ROS are not always 
pathological. It is a critical balance that the cells maintain for optimal survival. ROS 
are important second messengers who regulate numerous pathways and redox 
regulated transcription factors like Nf-Kb and AP1 and steer cells towards cell growth 
and survival (Bubici et al., 2006; Clerkin et al., 2008). Furthermore, a slight increase 
in intracellular ROS, and specifically O2.-, has been shown to favour survival by 
antagonizing apoptotic execution and/or via promoting survival signals (Ahmad et al., 
2003; Clement et al., 2003; Clement and Stamenkovic, 1996; Pervaiz et al., 2001). 




 Figure 3: Generation of ROS and their control by antioxidants. The principal 
sources of ROS as mentioned above and the antioxidant defences which would be 
described in greater detail in the next section. Abbreviations: CAT, catalase; CI, CII, 
CIII, CIV, and CV, respiratory chain complexes I, II, III, IV, and V; CO, 
cyclooxygenase; HNE, 4 hydroxy nonenal; iNOS, inducible nitric oxide synthase; 
LO, lipoxygenase; MDA, malonylaldehyde; MnSOD, manganese superoxide 
dismutase; mtNOS, mitochondrial nitric oxide synthase; NO, nitric oxide; MPO, 
myeloperoxidase; P-450-Oxy, cytochrome P450-dependent oxygenases; XO, xanthine 
oxidase; XDH, xanthine dehydrogenase; XOR, xanthine oxidoreductase; LPO, lipid 
peroxidation; ROOH, alkyl hydroxides. (Zacks et al., 2005) 
 
4. THE CELLULAR ANTIOXIDANT DEFENCE 
Given the dual effects of ROS, maintaining an optimal cellular redox balance is 
pertinent for cell survival. As such, cells are well adapted to resisting changes in this 
balance. In the previous sections, the mechanisms that can contribute to an increase in 




strategies cells have developed to combat oxidative insults will be reviewed (Figure 3) 
(Halliwell, 1999; Imlay, 2008).  
Anti–ROS mechanisms can fall under two broad categories. One would be the 
minimization of intracellular ROS production and the other would be to scavenge the 
ROS that are being produced. Since the mitochondria are a major producer of ROS in 
the cells, maintaining an efficient transport of electrons down the ETC minimizes the 
production of O2.-. Studies have shown that during aerobic respiration the 
mitochondria utilize low O2 concentrations. This is possible as the cytochrome 
oxidase remains very active even at these concentrations (Skulachev, 1997, 1998). 
Thus, in this way, the cells can minimize the production of high rates O2.-  as they can 
suffice with low intracellular and, more specifically low intra mitochondrial level of 
oxygen (Halliwell, 1999). However, this generation of ROS may increase with 
lowered COX activity due to the decreased oxygen consumption that leads to a 
concomitant rise in the reduced one electron donors in the ETC, thus enhancing their 
reduction of the oxygen In this regards, a higher COX activity is often associated with 
higher mitochondrial efficiency and reduced rates of O2.-  production (Papa and 
Skulachev, 1997; Skulachev, 1997). Despite having a tightly coupled electron 
transfer, leakage of electrons can still induce ROS production alongside other cellular 
ROS inducing processes or oxidative triggers. Thus an efficient antioxidant defence 
system is necessary to scavenge the ROS and maintain a favourable balance of ROS 





4.1 Superoxide Dismutases 
O2.- is the precursor to many reactive oxygen species such as H2O2, peroxynitrite and 
hydroxyl radicals. As such, it is one of the main mediators of oxygen toxicity both 
directly and indirectly. In the cells, the ETC, xanthine oxidases, NADPH oxidases, 
NOS are major sources of O2.-. O2.- can undergo spontaneous dismutation to produce 
H2O2 and O2 and this reaction is highly pH dependant (Halliwell, 1999).  
This process of spontaneous dismutation however, can be greatly accelerated by 
superoxide dismutases (SOD) (McCord and Fridovich, 1969a, b). There are three 
forms of SODs in human cells. SOD1 (copper zinc SOD) is located in the cytoplasm. 
SOD2 (manganese SOD) is in the mitochondria and SOD3 is extracellular. The 
presence of this enzyme in different sub cellular localizations is critical as O2.- cannot 
readily cross cell membranes due to its charged nature. Thus the SODs help to 
scavenge the O2.- produced in their respective vicinities before they elicit any 
deleterious effects. SOD1 and SOD3 contain copper and zinc while SOD2 uses 
manganese at the reactive centre. In CuZn SOD the copper ions participate in the 
dismutation reaction by undergoing alternate oxidation and reduction while the zinc 
ions are believed to enhance the stability of the SOD (Fridovich, 1975; Halliwell, 
1999; Kellogg and Fridovich, 1975).  
The net reaction that results from the action of SOD is 
 O2.- + O2.- + 2H+              H2O2 + O2 
In normal cells, an increased expression of SODs is favoured in protecting the cells 
from oxidative stress (Serra et al., 2003), whereas tumour cells seem to prefer a 
reduced expression of SODs. It is postulated that SODs could act as tumor 




difference in SOD activity in normal cells and cancer cells has been explored by 
several groups to help target cancer cells (Kobayashi et al., 1996; Oberley and 
Buettner, 1979; Plymate et al., 2003; Zhang et al., 2002). 
4.2 Catalase 
Both spontaneous dismutation and SOD activity leads to the production of H2O2 in 
the cells. In addition, intracellular H2O2 is generated by a wide variety of sources such 
as urate oxidases and D-amino acid oxidase (Chance et al., 1979). Due to its 
uncharged nature, H2O2 moves freely across membranes. In cells undergoing aerobic 
respiration, H2O2 is primarily removed by catalases and peroxidases.  
Animal catalases comprise four subunits, containing a ferric haem group each at its 
active centre (Reid et al., 1981) and they drive the decomposition of H2O2 to O2.  
2H2O2  2H2O + O2 
However, the catalase reaction in itself is essentially a disproportionation reaction as 
it involves the reduction of one H2O2 to H2O and the oxidation of another H2O2 to O2. 
Since the maximal velocity for the reaction between catalase and H2O2 is very high, it 
is difficult to saturate catalase (Halliwell, 1999). Thus, for the removal of a fixed 
amount H2O2, the rate of removal is very much dependant on the cellular 
concentration of catalase. Catalase is believed to be primarily localized in subcellular 
organelles known as peroxisomes. Some evidence suggests that it might be localized 
in the cytosol and minimally in mitochondria, if at all (Chance et al., 1979; Halliwell, 
1999). Thus, any H2O2 generated in the cell has to diffuse to these catalase rich 
regions in order to be decomposed by the catalases. However, catalases though 




4.3 Glutathione and Glutathione Dependant Enzymes 
4.3.1 Glutathione 
The glutathione redox system is one of the key artilleries against intracellular 
oxidative attacks. Glutathione (GSH) is a thiol tripetide (L-γ-glutamyl-L-
cysteinylglycine) that contains an unusual γ-peptide bond between glutamate and 
cysteine (Figure 4) where the carboxylic acid of the side chain of glutamate 
participates in the peptide bond formation. This bond makes GSH resistant from being 
hydrolyzed by most peptidases (Anderson, 1998; Meister and Anderson, 1983).  
      
glycine cysteine 
glutamate 
Figure 4: Structure of Glutathione (Anderson, 1998) 
GSH is ubiquitously expressed in animal tissues, plants and micro organisms. In 
animal tissues, it is found at concentrations ranging from 0.1mM to 10mM (Meister, 
1988b) and approximately (85-90) % of cellular GSH is present in the cytosol, with 
the remainder in organelles including the mitochondria, nuclear matrix, and 




 Figure 5: Overview of GSH metabolism (Anderson, 1998) 
GSH plays several important functions in the cell (Figure 5). GSH acts as a cofactor 
for several enzymatic reactions (e.g. glutathione peroxidases) and participates in 
various metabolic pathways like leukotrienes synthesis. It is also involved in the 
synthesis of proteins and nucleic acids in the cell and serves as a storage and means of 
transport for cysteine moieties. The glutathione redox cycle (Figure 6) also plays a 
critical role in protecting cells from toxicity mediated by oxygen and its derivatives 
(Anderson, 1998; Meister, 1988a, b; Meister and Anderson, 1983)  
The process of glutathione mediated detoxification occurs mainly via three 
mechanisms. Firstly, GSH can react enzymatically with toxic compounds to form 
conjugates. This reaction is catalysed by the GSH S-transferase family of proteins. An 
example would be conjugation of GSH with NO to form an S-nitroso-glutathione 
adduct which is then acted upon by the thioredoxin system (Fang et al., 2002) 
Secondly, it can participate in non enzymatic chemical reactions with reactive 
metabolites to form conjugates and detoxify them. Lastly, the thiol group of cysteine 




metabolites such as hydrogen peroxide or organic peroxides (Timbrell, 2008). This 
results in the oxidation of GSH to glutathione disulfide (GSSG).  
Accumulation of GSSG in the cells can occur as a consequent of oxidative stress. 
Indeed, the intracellular GSH/GSSG ratio (Schafer and Buettner, 2001) is used as an 
indicator of the cellular redox status and a critical determinant of oxidative stress. 
Since GSSG build-up can have detrimental intracellular effects  
(Dringen, 2000; Filomeni et al., 2003), cells actively try and maintain a high 
GSH/GSSG ratio that confers a highly reducing environment, keeping the 
intracellular environment less susceptible to oxidative damage (Halliwell, 1999). 
They keep up this ratio by GSH synthesis, reduction of GSSG back to GSH via GSSG 
reductase and GSSG export (LaBelle et al., 1986; Sen et al., 1993; Srivastava and 
Beutler, 1969) from the cells.  
4.3.2 GSH synthesis 
GSH synthesis requires the action of γ-glutamylcysteine synthetase and GSH 
synthetases (Figure 5).  The first step, which is also the rate limiting reaction involves 
the catalysis of dipeptide formation by γ-glutamylcysteine synthetase. 
L-glutamate + L-cysteine + ATP               L- γ-glutamyl-cysteine + ADP + Pi  
Subsequently, L- γ-glutamyl-cysteine is converted to GSH by GSH synthetase 
(Halliwell, 1999; Meister, 1988a, b; Meister and Anderson, 1983)  




γ-Glutamylcysteine synthetase, also known as glutamate cysteine ligase (GCL) is a 
heterodimeric enzyme. It constitutes the catalytic subunit (GCLC) that confers the 
total enzymatic activity and the modulatory subunit that can alter the efficiency of the 
catalytic subunit. Altered expressions of these subunits and, more importantly GCLC 
have been shown to modulate GSH synthesis (Beutler and Gelbart, 1986; Huang et 
al., 1993).  
4.3.3 Glutathione Reductase 
The GSSG produced in the cell under normal conditions is reduced back to GSH by 
the widely distributed flavoprotein glutathione reductase (GR). This enzymatic 
reaction requires NADPH (Figure 5 & Figure 6).  
GSSG + NADPH + H+           2GSH + NADP+ 
NADPH reduces flavin adenine dinucleotide (FAD) present in GR to produce a 
transient FADH- anion. This anion then quickly breaks the redox active disulfide bond 
in GR and nucleophilically attacks the nearest sulfide unit in the GSSG molecule 
yielding a mixed disulfide bond and a GS- anion. GR then protonates the GS- anion to 
form the first GSH. A nucleophilic attack by a nearby cystein residue onto the mixed 
disulfide bond formed earlier leads to the release of a second GS- anion which is 
protonated in solution and released from the enzyme, resulting in the second GSH. 
This process then reforms the redox active disulfide (Pai and Schulz, 1983). Glucose 
metabolism plays a crucial role in providing for NADPH via the pentose phosphate 
shunt and a deficiency in intracellular NADPH can exacerbate an imbalance between 
the production and scavenging of free radicals. Indeed, it has been shown in several 




system in the cells and protect them from ROS mediated cell death (Kowaltowski and 
Fiskum, 2005; LeGrand and Aw, 1998; Pias and Aw, 2002). 
4.3.4 Glutathione Peroxidase 
Glutathione Peroxidase (GPx) enzymes belong to a family of selenoproteins whose 
function is to catalyze the reduction of peroxides. In mammalian cells, four types of 
GPxs have been identified. These four contain selenocysteine at their active site 
(Arthur, 2000; Halliwell, 1999). They catalyze the reaction of hydroperoxides with 
reduced glutathione (GSH) to form oxidized glutathione disulfide (GSSG) and the 
reduction product H2O (Chance et al., 1979). GPxs are believed to act via the 
oxidation of the active site selenolate (Se-) to selenenic acid (SeOH). GSH reacts with 
selenenic acid to produce a selenenylsulfide adduct (Se-SG). The active site can be 
regenerated to selenolate by the addition of a second GSH. This reaction utilizes two 
molecules of GSH to produce GSSG as an end product. 
ROOH + 2GSH            ROH + GSSG + H2O 
More specifically, the removal of H2O2 follows the reaction below 
H2O2 + 2GSH            GSSG + H2O 
These peroxide degrading enzymes are widely distributed in animal tissues and are 
highly specific for their hydrogen donor GSH with the exception of type IV GPx 
which utilizes GSH and other reducing substrates (Maiorino et al., 1995).  
Intracellular GPx is largely found in the cytosol with approximately 10% at the 
mitochondria. Because mitochondria have no catalase (Neubert et al., 1962), they rely 
largely on GSH peroxidase to detoxify hydroperoxides. The distribution of GPx 




peroxisomes where catalase predominantly resides. In this way, an efficient H2O2 
degrading system is available in all parts of the cell. 
 
Figure 6: Diagrammatic representation of the glutathione redox cycle Glutathione 
peroxidase (GPx) reduces peroxides while oxidizing GSH to GSSG. Glutathione 
reductase (GR) reduces GSSG back to GSH with reducing equivalents derived from 
NADPH (Padgett and Whorton, 1995). 
4.4 Peroxiredoxins  
Peroxiredoxins (Prxs) are a family of thioredoxin dependant peroxidases enzymes 
involved in the enzymatic degradation of H2O2, organic hydroperoxides and 
peroxynitrites (Hofmann et al., 2002; Rhee et al., 2001; Rhee et al., 1999). They are 
present in a variety of organisms such as bacteria, plants and mammals and, in 
mammalian cells, six isoforms have been identified. These Prxs can be divided into 
three major subclasses: typical 2-cysteine Prxs (Prx I-IV), atypical 2-cysteine Prx (Prx 
V) and 1-cysteine Prxs (Prx VI) based on the number and position of cysteine residues 
that participate in catalysis (Rhee et al., 2001; Seo et al., 2000). All Prx contain a 
conserved cysteine residue at the N terminus that undergoes a cycle of peroxide-
dependent oxidation and thiol-dependent reduction during catalysis. Prx I-IV contain 
an additional conserved cysteine residue at the C terminus which is absent in PrxV 
and Prx VI (Rhee et al., 2005a). Prx I, II IV and VI are localized to the cytosol and 
Prx III is mainly localized to the mitochondria. Prx V is localized in the cytosol and 
the mitochondria. Though Prx I and Prx II are catalytically less efficient then GPx or 




affinity to H2O2. Thus, they are the prime candidates as regulators of H2O2 signalling 
(Rhee et al., 2005a).  
During catalysis, the active cysteine residue present in Prx is oxidized to cysteine 
sulfenic acid (Cys-SOH) with the reduction of peroxides. Cys-SOH is unstable and 
can react with any accessible thiols to form disulfides and can be reduced back to the 
active thiols via the thioredoxin-thioredoxin reductase system (Figure 8). However, 
the process of disulfide formation is slow. Hence, under conditions of oxidative stress, 
Cys-SOH undergoes further oxidation to sulfinic acid (Cys-S02H) or sulfonic acid 
(Cys-S03H) which can result in the inactivation of the enzyme (Hofmann et al., 2002; 
Wood et al., 2003a; Wood et al., 2003b).  
More recent studies however, suggest that overoxidised forms of Prxs can be reduced 
back to active forms during the recovery process ensuing oxidative stress (Budanov et 
al., 2004; Chevallet et al., 2003; Jonsson and Lowther, 2007; Woo et al., 2003a). 
These studies have challenged the previous motion that hyperoxidation of Prxs is 
irreversible. The discovery of the peroxiredoxin repair proteins (Jonsson and Lowther, 
2007) such as sulfinic acid reductases, sulfiredoxins (Srx) (Biteau et al., 2003) and 
sestrins (Budanov et al., 2004), has shown that hyperoxidation of Prxs is a reversible 
process and has put forth a new notion that Prxs may be critical regulators of peroxide 
mediated cell signalling by acting as a sulfinic acid switch (Jacob et al., 2004). They 
suggest that this may occur since the catalytic reduction of Prxs is a slow process, thus 
keeping them inactive for a prolonged period and this would lengthen the intracellular 




 Figure 7: Catalytic and inactivation/reactivation cycles of Prxs. Prx disulfides are 
catalytically reduced by thioredoxins. Hyperoxidised Prxs are reduced by 
sulfiredoxins (Rhee et al., 2005a). 
4.5 Thioredoxins 
The mammalian thioredoxins (Trxs) are a family of small (approximately 12 kDa) 
redox proteins. The Trx system comprises of Trx and Trx reductase (TrxR). Trxs of 
all organisms contain a conserved -Cys-Gly-Pro-Cys- active site. Trxs utilize their 
active site to reduce the disulfides present in proteins and peptides including Prx and 
GSSG (Figure 8) (Holmgren, 2000; Holmgren and Bjornstedt, 1995). TrxR then 
reduces the oxidized cysteine groups found in Trx and other proteins and low 
molecular weight compounds in an NADPH-dependent reaction.  
 
Figure 8: Enzymatic reactions of the thioredoxin system. Thioredoxin reductase 
(TrxR) reduces the active site disulfide in thioredoxins (Trx) and several other 
substrates directly under consumption of NADPH. Reduced thioredoxin is highly 
efficient in reducing disulfides in proteins and peptides, including peroxiredoxins 




 The two main Trx are Trx-1, which can be found in the cytosol and nucleus, and Trx-
2, a mitochondrial form.  Trx-1 has been explored more extensively and is known to 
perform many important functions which include supplying reducing equivalents to 
thioredoxin peroxidases and ribonucleotide reductase, the regulation of transcription 
factor activity and the regulation of enzyme activity by heterodimer formation (Figure 
9). Studies are also showing that Trx-1 levels are elevated in tumors and they can 
contribute to cell growth and inhibit cell division (Holmgren and Bjornstedt, 1995; 
Nordberg and Arner, 2001; Powis and Montfort, 2001).  
 
Figure 9: Graphic summary of major physiological functions of the mammalian 
thioredoxin system. (Nordberg and Arner, 2001) 
 
5. hTERT AND ROS 
The focus of this work, in part, is to unravel the cellular cross talk between hTERT 
and ROS. As such, having reviewed hTERT and ROS individually, this section will 
attempt to consolidate and present the findings made by other groups on the 




5.1 Effects of oxidative stress on hTERT 
As already outlined in the earlier sections, TERT expression is regulated by many 
transcription factors, several of which are redox regulated. Some of these key 
regulators include AP1, SP1 and Nf-kB, all of which are redox regulated (Akiyama et 
al., 2003; Cong and Shay, 2008; Cong et al., 2002; Poole et al., 2001; Takakura et al., 
2005). AP1 has been shown to be a suppressor of hTERT whilst SP1 and Nf-kB have 
been shown to be activators of TERT. Given that activation or suppression of these 
transcription factors of TERT are redox regulated, TERT is inevitably affected by the 
intracellular redox conditions. For instance, work in promyelocytic leukaemia cells 
demonstrated that arsenic induced ROS downregulated hTERT expression via the 
oxidation of the transcription factor SP1 thus leading to reduced binding of SP1, to 
hTERT and c-myc promoter (Chou et al., 2005; Chou et al., 2001). Since c-myc is 
also a critical transcriptional regulator of hTERT, this may further contribute to the 
reduction of hTERT expression. In addition to being transcriptionally affected by 
redox conditions, ROS can also alter TERT’s intracellular localization, thus altering 
cell fate.  
Incubation with H2O2 has been shown to induce the reversible export of TERT from 
the nucleus to the cytosol. This export is initiated by ROS induced phosphorylation of 
TERT by Src kinases at tyrosine 707. Treatment with antioxidants such as N-
Acetylcysteine (NAC) could inhibit this nuclear export and delay the onset of ROS 
induced replicative senescence. Furthermore, inhibition of nuclear export of hTERT 
was demonstrated to enhance the antiapoptotic activity of hTERT against ROS-




been shown to associate with hTERT following TNF-a treatment and chaperone 
hTERT into the nucleus (Akiyama et al., 2003).  
Extranuclear telomerase has also been shown to colocalize to the mitochondria 
following oxidative stress, the function of which is yet to be fully understood (Ahmed 
et al., 2008; Massard et al., 2006; Passos et al., 2006; Santos et al., 2004; Santos et 
al., 2006). However, the role it plays at the mitochondria is yet to be fully understood. 
Findings by Santos et al demonstrate that the localization of hTERT to the 
mitochondria resulted in increased mitochondrial DNA damage following acute 
oxidative stress. According to their findings, hTERT expression did not alter the rate 
of H2O2 breakdown. However, they found higher levels of chelatable metal ions in the 
hTERT expressing cells and suggested that the damaging effects of hTERT could be 
modulated by the elevated levels of divalent metal ions via Fenton chemistry (Santos 
et al., 2004; Santos et al., 2006) In contrast to these findings, several studies have 
shown the reverse (Ahmed et al., 2008; Massard et al., 2006; Passos et al., 2007). 
Gorbunova et al showed that hTERT expression was unable to prevent stress induced 
premature senescence following exposure of the normal cells to UV, γ-irradiation, and 
H2O2. However the expression of hTERT could protect the cells from apoptosis and 
necrosis elicited by these agents. They hypothesized that the repair of DNA breaks by 
telomerase could protect them from cell death, but, because this does not provide 
legitimate DNA repair, it could not protect cells from stress induced premature 
senescence (Gorbunova et al., 2002). In addition, it has also been illustrated that 
hTERT depletion can facilitate Bax conformational change and sensitizes cells to 




5.2 Effects of hTERT on oxidative stress 
Oxidative stress regulates hTERT at many levels. It regulates its expression, activity, 
modulates its localization and, in doing so, alters its functions. The current question is 
however, whether telomerase can play a reverse role and modulate intracellular redox 
status. Some very recent findings are beginning to suggest that hTERT may influence 
cellular redox status. In this light, Ahmed et al recently showed that MRC-5 lung 
fibroblasts expressing telomerase showed a significant translocation of hTERT to the 
mitochondria following oxidative stress and this was followed by lowered 
mitochondrial DNA damage, peroxide levels and an increase in mitochondrial 
membrane potential (Ahmed et al., 2008). Several papers  have also suggested 
improved cellular response against oxidative stress in hTERT overexpressing cells 
(Armstrong et al., 2005; Beliveau and Yaswen, 2007; Dairkee et al., 2007; Lee et al., 
2005; Lorenz et al., 2001; Mondello et al., 2006). However, the reasons or 
mechanisms that could contribute this improved resistance to oxidative stress remain 
elusive. 
Several studies have suggested that hTERT expression in cells can help to improve 
the mitochondrial function by improving calcium storage and reducing mitochondrial 
superoxide formation (Ahmed et al., 2008; Del Bufalo et al., 2005; Massard et al., 
2006; Passos et al., 2007).  Gene profiling studies by Bagheri et al established that 
telomerase activity can control several glycolytic pathway genes, thus altering the 
energy state of tumour cells. In addition, they also showed that telomerase 
downregulation can lead to a decrease in glucose consumption and lactate production 
(Bagheri et al., 2006). More recently, it was reported that mitochondrial TERT can 




respiratory chain activity and protecting against oxidative stress–induced damage 
(Haendeler et al., 2009). In their studies, mitochondria isolated from TERT-/- mice 
displayed a significant reduction in complex I dependant respiration as compared to 
TERT wild type mice. They then went on to identify 2 regions containing the coding 
sequences for NADH: ubiquinone oxidoreductase (complex I) subunit 1 and 2 (ND1, 
ND2) as interaction sites for TERT. Haendeler et al speculated that mitochondrial 
TERT may counteract ROS production by complex I by binding to the ND1 and ND2 
genes, thereby increasing the synthesis of functional complex I subunits which, in 
turn, can reduce the formation of damaged complex I that leaks electrons onto 
oxygen, thus conferring survival advantages. Based on these studies it is tempting to 
speculate that the improved cellular resistance to oxidative stress can be in part due to 
improved mitochondrial function.  
Though many studies have shown that hTERT overexpression confers survival 
advantages against ROS mediated cell death triggers, the underlying mechanisms or 
the changes in intracellular milieu that ensues to serve this protection remains 
questionable, especially in the context of cancer cells and, perhaps, understanding the 
cell death mechanisms may explain the possible routes via which hTERT expression 
could confer its protective effects. 
6. CELL DEATH 
Cell death is part of the normal development and maturation cycle. The homeostatic 
balance between proliferation and cell death is important for healthy development of 
an individual. Alterations or defiance against these natural death mechanisms can lead 
to diseases such as AIDS, ischemia, neurodegenerative diseases (such as Parkinson’s 




regards, improving therapeutic efficacy and selectivity against diseases such as cancer 
remains a challenge for pharmaceutical companies and researchers. Though cancer 
therapeutics favour a multi prong approach where individual treatment varies between 
surgery, radiation, chemicals, antibodies and/or cells of the immune system, the 
effectiveness of the treatment differs largely between individuals and the background 
of the cancer (Zornig et al., 2001) This is largely due to the constant evolution of 
neoplastic cells against death triggers. As such characterization of death mechanisms 
is imperative for improved treatment. Over the years extensive work in the field of 
cell death has helped to map out the few primary mechanisms of cell death; namely 
necrosis, autophagy and apoptosis (Kroemer et al., 2009).  
6.1 Necrosis  
My imagination serves to picture necrosis as a condition where the cell spills its guts 
out and its toxicity invades and destroys the surrounding cells. Reality is not too far 
from my imagination. A necrotic stimulus can damage the mitochondria electron 
transport chain, thus disrupting ATP production and leading to mitochondrial 
depolarization. Electrons that leak from the damaged electron transport chain can then 
lead to ROS formation (Reed, 2002).  The ROS induced cellular damage that ensues 
can disrupt the integrity of the cellular membrane resulting in cellular swelling, 
rupture of the plasma membrane and lysosomes, (Zong and Thompson, 2006) 
releasing a concoction of digestive enzymes and hydrolytic fluids. This potent mixture 




6.2 Autophagy  
Autophagy (from the Greek, “auto” oneself, “phagy” to eat) is a catabolic process that 
involves the degradation of a cell's own components via the delivery of cytoplasmic 
cargo to the lysosomal machinery. Several forms of autophagy have been discovered 
over the years which include chaperone-mediated autophagy, microautophagy and 
macroautophagy (Levine and Kroemer, 2008). They vary in their physiological roles 
and the mode of cargo delivery to the lysosome and, amongst these, macroautophagy 
has been extensively studied; for it is a major highly regulated catabolic mechanism 
that eukaryotic cells use to degrade long-lived proteins and organelles. During this 
process, the cytoplasmic contents are engulfed in a double-membraned structure 
known as the autophagosome, which then fuses with lysosomes to form 
autolysosomes. Here, the engulfed contents are degraded by lysosomal hydrolases 
(Lockshin and Zakeri, 2004). The process of autophagy is especially essential in times 
of starvation for it is employed by cells to break down non-vital components and 
releases the nutrients, thus ensuring that vital processes can continue (Levine and 
Klionsky, 2004).  
6.3 Apoptosis 
Apoptosis is characterized by cell shrinkage, blebbing of plasma membrane, 
maintenance of organelle integrity, condensation and fragmentation of DNA, 
followed by ordered removal of phagocytes (Kerr et al., 1972). Unlike necrosis, 
apoptosis works like a ‘suicide’ program and it causes minimal damage to 
surrounding tissues. Apoptosis has been sub classified into two types of death 




exclusive and evidence suggests that they are linked and that molecules in one 
pathway can influence the other (Danial and Korsmeyer, 2004). 
6.3.1 Type I – Extrinsic or Receptor Mediated Pathway 
Type I is the extrinsic receptor mediated death pathway that requires effective 
engagement between the death receptors found on the surface of the cell membranes 
and ligands. The receptor mediated pathway involves death receptors from the tumour 
necrosis factor (TNF) superfamily such as TNF, CD95 (Fas) and TNF-related 
apoptosis inducing ligand (TRAIL) receptors. These receptors have an extracellular 
domain to engage the ligands and an intracellular cytoplasmic domain that is also 
referred to as the death domain. This death domain is responsible for transmitting the 
death signal from the surface to the intracellular signalling pathways (Ashkenazi and 
Dixit, 1998). Activation of CD95 or TNF receptors often leads to receptor clustering 
and intracellular recruitment of proteins into a death-inducing signalling complex 
(DISC), which then activates an initiator caspase, procaspase 8. Activated caspase 8 
then triggers the execution phase of apoptosis via the activation of downstream 
effector caspase 3 (Hengartner, 2000). The activated caspases can then induce 
mitochondrial damage and reinforce the death signal by engaging the mitochondria 
mediated pathway (Elmore, 2007; Fesus et al., 1991; Rudin and Thompson, 1997; 
Schultz and Harrington, 2003). 
6.3.2 Type II – Intrinsic or mitochondria mediated pathway 
The mitochondria pathway of cell death can be activated by a variety of receptor-
independent stimuli such as radiation, free radicals, viral infections and serum/growth 




mitochondrial membrane that result in an opening of the mitochondrial permeability 
transition (MPT) pore. This leads to the loss of the mitochondrial transmembrane 
potential and the release of pro-apoptotic proteins. The proteins that are released can 
be broadly classified into two categories. The first category comprises of proteins that 
can activate the caspase dependant pathway and it would include proteins such as Cyt. 
C and SMACs (second mitochondria-derived activator of caspases). The 
holocytochrome c (Cyt. C) then induces Apaf-1 oligomerization, leading to activation 
of caspase 9. This active cytochrome/Apaf-1/caspase 9 complex forms the 
apoptosome and activates the executioner caspases 3 and 7 resulting in the 
degradation of the cells through nuclear fragmentation (Gross et al., 1999; 
Hengartner, 2000; Slee et al., 1999) . SMAC binds to IAPs (inhibitor of apoptosis 
proteins) and deactivates them, thus preventing the IAPs from arresting the apoptotic 
process and, therefore allowing apoptosis to proceed. Bcl-2 overexpression has been 
shown to block apoptosis in these type II cells.  
The second category would include other pro-apoptotic proteins such as apoptosis 
inducing factor (AIF) and endonuclease G. The release of these proteins is a late event 
in apoptosis which occurs once the cells are commited to die. Following the release of 
AIF, it translocates to the mitochondria where it results in DNA fragmentation. 
Similarly endonuclease G also translocates to the nucleus and cleaves nuclear 
chromatin. Both AIF and endonuclease G act in a caspase independent manner to 
execute cell death (Joza et al., 2001).  
6.4 Influence of ROS on cell death signalling 
Even though ROS does not act directly through the cell receptors, it can influence the 




conducive for effective engagement between receptors and ligands or the execution of 
the downstream stream events leading to apoptosis. Receptor upregulation has been 
observed in several systems with exogenous ROS or ROS inducing agents. 
Upregulation of CD95 and TRAIL death receptors have been observed in response to 
H2O2 (Woo et al., 2004). In addition, intracellular ROS induced by treatment with 
cisplatin also promoted surface clustering of CD95 and treatment with antioxidants 
could abolish this clustering (Huang et al., 2003). Furthermore, ROS has also been 
shown to sensitize TRAIL induced cell death (Izeradjene et al., 2005). The induction 
of intracellular ROS following treatment with TRAIL has also been shown to result in 
caspase activation which drives the cells further into the path of death (Lee et al., 
2001). Caspases are critical downstream executioners which work most effectively 
under reducing conditions. However, exposure of cells to a slight pro-oxidant state 
has been shown to result in the oxidation of caspases at the catalytic cysteine residues 
rendering them ineffective and the cells resistant to caspase dependant apoptotic 
triggers (Clement and Pervaiz, 1999; Pervaiz et al., 1999a). Thus, ROS can play a 
dual role with regards to apoptosis by modulating the cellular environment. 
The intrinsic pathway of cell death is especially susceptible to ROS. Previously, we 
have shown in our lab that exogenous addition of H2O2 has an inhibitory effect on 
Na+/H+ exchanger activity resulting in cytosolic acidification, which creates a 
conducive environment for apoptosis (Akram et al., 2006; Kumar et al., 2007) and, 
similarly, exposure of cells to the experimental drug C1 has also been shown to 
induce intracellular H2O2 which then results in an acidic intracellular milieu. 
Following acidification, Bax undergoes a conformational change and translocates to 
the mitochondria. Its insertion into the outer mitochondrial membrane leads to the 




release of apoptogenic factors (Ahmad et al., 2004; Hirpara et al., 2001). The inner 
mitochondrial protein, ANT, is also a target of ROS modulation by virtue of its redox-
sensitive cysteines, providing an additional mechanism by which drug-induced ROS 
production may cause apoptosis. Oxidation of the cysteine residues can also result in 
mitochondrial permeability transition pore complex opening, leading to the release of 
pro-apoptogenic factors and induction of cell death (Costantini et al., 2000).  
 
Figure 10: Apoptotic pathways. Two major pathways lead to apoptosis: the intrinsic 
cell death pathway controlled by Bcl-2 family members and the extrinsic cell death 




6.5 Mitochondria Membrane Permeabilization 
The mitochondria is enveloped in two membranes commonly referred to as the inner 
and the outer mitochondrial membranes (OMM)  (Henze and Martin, 2003). The inner 
mitochondrial membrane (IMM) surrounds the inner mitochondrial matrix and is 
folded into the numerous cristae, while the outer mitochondrial membrane surrounds 
the inner membrane, thus creating the intermembrane space. The intermembrane 
space is where many of the pro-apoptotic proteins such as Cyt. C, SMAC and AIF are 
stored. In healthy cells, the IMM is impermeable to all ions (Kroemer et al., 2007). 
This allows the electron transport chain to actively build up the proton gradient across 
the IMM. The inner mitochondrial transmembrane potential (m) results from the 
difference in charges that is generated by the electrochemical gradient across the 
IMM. This proton gradient is then used to drive ATP synthesis via ATP synthase that 
is located at the IMM. As such, the maintenance of the proton gradient is imperative 
for survival and is a tightly regulated mechanism (Desagher and Martinou, 2000; 
Kroemer et al., 2007; Mitchell and Moyle, 1965a, b).  
Permeabilization of the outer mitochondrial membrane often occurs as an outcome of 
proapoptotic signals that directly promote the destabilization of mitochondrial lipids, 
thus favouring the formation of pores and the release of proteins from the inner 
mitochondrial space. The members of the Bcl-2 family can highly regulate to enhance 
or diminish the integrity of the mitochondrial membrane (De Giorgi et al., 2002).  
The permeability transition pore complex (PTPC) is a high conductance channel 
formed by the association of several proteins including VDAC (voltage-dependent 
anion channel), ANT (adenine nucleotide translocator) and cyclophilin D. This 




changes in pH and association with proteins such as Bax can lead to the opening of 
the pore and the sudden increase in the permeability of the IMM that can contribute to 
the dissipation of the m. This then leads to a rapid swelling of the matrix that has a 
high solute content and the subsequent rupture of the OMM and release of the 
intermembrane space proteins (Crompton, 1999; Desagher and Martinou, 2000).  
 
Figure 11: Hypothetical schematic of the mitochondrial permeability transition 
pore. The mitochondrial membrane permeability transition pore is a conductance pore 
that spans the IMM and OMM. It consists of membranous elements such as the 
VDAC on the OMM, the ANT on the IMM, and cyclophilin D (Cyclo D) in the 
matrix. Other proteins, such as the peripheral benzodiazepine receptor (PBR), 
hexokinase (HK) and creatine kinase (CK), might also be associated with the PTPC. 
Under a combination of pathophysiological conditions, such as high Ca2+ 
concentration, increased oxidative stress, low ATP, and mitochondrial depolarization, 
the complex forms an open pore between the inner and outer membranes, allowing 
free diffusion of solutes across the membranes. The opening of the PTPC ultimately 
results in mitochondrial swelling, mitochondrial Ca2+ efflux and the release of 
apoptogenic proteins, such as Cyt. C and procaspases from the intermembrane space. 






6.6 Regulation of Apoptosis by the Bcl-2 Family of Proteins 
The apoptotic events are highly regulated by the Bcl-2 family of proteins which 
shares homology in any of the four common Bcl-2 homology (BH) domains. Thus, 
the Bcl-2 family of proteins has been divided according to the domains they carry. 
The anti-apoptotic proteins Bcl-2, Bcl-xl, Mcl-1 all contain domains BH1, 2, 3 and 4. 
They contain a hydrophobic carboxy terminal domain that enables them to dock into 
the outer mitochondria membrane (OMM), the nucleus and ER (Cory and Adams, 
2002). It has been shown that Bcl-2 and Bcl-xl can protects the cells by interacting 
with mitochondrial proteins such as ANT or VDAC, thus preventing them from 
forming mitochondrial pores and protecting the membrane integrity and inhibiting the 
release of apoptogenic factors such as Cyt. C (Brenner et al., 2000).  
The second category of Bcl-2 family of proteins contains BH domains 1, 2 and 3. 
These proteins would include Bax and Bak. Bax is a pro-apoptotic protein that resides 
in the cytosol under physiological conditions. An apoptotic trigger however, can lead 
to its translocation to the mitochodria and its subsequent insertion into the OMM. At 
the mitochondria, Bax can homodimerize or heterodimerize with other pro-apoptotic 
members such as Bak or truncated Bid, thus disrupting the integrity of the OMM by 
forming mitochondrial pores and increasing its permeability. These pores can then 
lead to the release of apoptogenic factors such as Cyt. C (Vyssokikh et al., 2002). 
Some reports have also suggested that Bax engages in a close molecular cooperation 
with proteins from the PTPC, such as ANT and/or VDAC, to induce mitochondria 
membrane permeabilization (MMP) (Marzo et al., 1998). Bcl-2 and Bcl-xl have been 
shown to antagonize the apoptotic cascade by a direct interaction and sequesteration 




inhibited by its interaction with VDAC) when it is freed can also homodimerize and 
result in pore formation at the mitochondria. 
The third group of Bcl-2 family of proteins is the BH3–only proteins. The BH3-only 
family members include Bim, Bad, Bmf, Noxa and Puma. They can act by 
neutralizing the anti-apoptotic proteins. For instance, Bim, Puma, Bad and Bmf can 
heterodimerize with Bcl-2 and Bcl-xl and sequester them, thus preventing them from 
protecting the mitochondria.  
7. CANCER THERAPY, ROS AND TELOMERASE 
The exploitation of the unique properties of cancer cells has been suggested by 
several studies to be valuable in the development of cancer therapy (Gellert G.C. et 
al., 2005; Trachootham et al., 2009). For instance, as neoplastic cells advance through 
the various stages of cancer they have been frequently observed to display higher 
genetic alterations and increased oxidative stress. Thus, it has been proposed that 
cancer cells might be more vulnerable to pharmacological ROS insults due to their 
elevated intracellular ROS levels (Kong et al., 2000; Kong and Lillehei, 1998). 
Indeed, many current day anticancer agents such as arsenic trioxide, anthracyclines, 
bleomycin and irradiation do induce ROS production in cells and this perturbation of 
the intracellular ROS balance has been shown to prime cells for effective execution of 
death (Pelicano et al., 2004).   
Cancer cells, on the other hand, have developed numerous counter evasive 
mechanisms to avoid engagement of the apoptotic program in the event of a cell death 
trigger. These mechanisms include enhanced drug efflux systems, mutation of critical 




mutations in pro-apoptotic proteins that result in defective death pathways and, 
perhaps, in this regard the reactivation of hTERT in cancer cells can also be viewed 
upon as a defensive strategy employed by cancer cells.  
This very distinction however, has also made telomerase a very attractive target for 
the design of telomerase inhibitors with the hope that off target effects would be 
minimal due to its lack of expression in most normal cells. But research in this arena 
is still relatively young with mixed outcomes (Corey, 2002; Gellert G.C. et al., 2005). 
For instance, while targeting hTERT mRNA by using anti-sense oligonucleotides has 
been reported to increase cell death by one group, another team has reported that there 
were little inhibitory effects in telomerase activity or cell proliferation (Natarajan et 
al., 2004; Shay, 2003). On the optimistic side however, telomerase inhibitors in 
general have shown some potential to shorten telomeres and induce apoptosis with 
prolonged treatment. Ribozymes that can target hTR or hTERT mRNA when 
introduced into cancer cells have resulted in the inhibition of telomerase activity, 
telomere shortening and apoptosis. Translating these studies to in vivo models have 
also shown some promising results with decreased tumour size in mice treated with 
ribozymes that can target telomerase RNA (Folini et al., 2000; Yeo et al., 2005). The 
use of dominant negative hTERT (DN-hTERT) has also been employed to test the 
effects on cancer cells. The DN-hTERT is catalytically inactive and it binds with hTR 
and reduces its availability to telomerase. This inevitably leads to a decrease in 
telomerase activity, telomere shortening and apoptosis (Delhommeau et al., 2002). 
Combinatorial treatment with DN-hTERT and chemotherapeutic agents such as 
cisplatin and etoposide has also been able to sensitize cancer cells to these drugs 




While these reports portray a promising future for the use of anti telomerase, and 
specifically, anti hTERT strategies, others have reported a lack of synergistic effect in 
the sensitization of cancer cells when combining telomerase inhibitors with drugs 
such as paclitaxel, doxorubicin, etoposide and cisplatin in short term studies. (Chen et 
al., 2003; Dudognon et al., 2004) These data bring to light the variables which must 
be considered carefully before administrating certain drug regiments alone or in 
combination. The differences in the cell lines, the time course over which the 
inhibitors are administered, the types of drugs to be used in combination and the doses 
of administration are key factors which will largely influence the outcomes of the 
therapeutic efficiency. 
The role of hTERT has evolved and diversified over the years. A new era of 
evidences has arisen that strongly suggest an important role for hTERT in protecting 
cells from ROS mediated apoptotic triggers and though there are some plausible 
explanations for the improved resistance, the exact mechanisms remain elusive and 
have yet to be unravelled. Given that many chemotherapeutic drugs employ ROS to 
elicit death signals in cancer cells, investigating the mechanisms hTERT employs to 
shield cancer cells from oxidative insults would certainly have huge implications in 
cancer therapeutics. For targeting and overriding the death defying ability of hTERT 









As outlined in the introduction, the literature suggests that there could be a 
relationship between hTERT expression and cellular redox status. In addition, hTERT 
has also been shown to confer a protective role against apoptotic triggers. Based on 
this, we developed a working hypothesis that hTERT might be able to influence the 
intracellular ROS levels directly or indirectly by regulating mechanisms imperative 
for cellular redox balance and confer the cells the ability to resist a surge in 
intracellular ROS levels following oxidative stress and, hence, survive ROS mediated 
apoptotic triggers. To do so, my specific aims were: 
Aim 1: To establish a cell based model to evaluate the cross talk between 
hTERT and ROS 
hTERT activation in cancer cells is imperative to the maintenance of telomere lengths 
and the enhanced replicative capacity.  Whereas the conventional oncogenic role of 
hTERT has been linked to its ability to overcome replicative senescence and 
immortalization, evidence is accumulating to support the non-canonical activity of 
hTERT in cancer cells and, more specifically, the protection it confers against ROS 
mediated apoptosis. As such, this study originated with the aim of establishing how 
hTERT can be modulated by ROS and more critically, if hTERT can modulate the 
intracellular redox status, thus bestowing survival advantages onto the cells. 
 To study the effects ROS can elicit on hTERT expression, activity and 
localization. 
 Investigate by hTERT overexpression the effects hTERT can have on 
basal intracellular redox status and intracellular ROS levels following 




Aim 2: To assess how hTERT expression can modulate intracellular ROS 
levels 
Following our studies, on how hTERT modulates intracellular redox status, we 
wanted to unravel how the cellular ROS levels are being changed by the 
absence/presence of hTERT. Alterations to intracellular redox status are often brought 
about by two primary mechanisms, namely the cellular antioxidant defences and 
alterations in mitochondrial function. Improved antioxidant defences can improve the 
cellular capacity to withstand oxidative insults while efficient mitochondria can 
reduce the aberrant production of cellular ROS. 
 Check the levels and activity of the key cellular antioxidant defences 
 Study if hTERT can localize to the mitochondria and how hTERT can 
modulate mitochondrial function 
 Investigate the effects of hTERT expression on cellular redox status 
and antioxidant defences in other cell lines 
Aim 3: To understand how hTERT expression can alter intracellular milieu 
and alter the engagement of cell death pathways. 
We have previously shown that alterations in the cellular redox status can change the 
intracellular milieu making it conducive for the execution of death (Ahmad et al., 
2004; Akram et al., 2006; Clement and Pervaiz, 1999; Hirpara et al., 2001). Thus, we 
asked if the resulting decrease in ROS levels in the presence of hTERT expression can 
alter the intracellular milieu making the environment unfavourable for the execution 
of death pathways. 
 Intracellular pH levels were assessed following treatment with ROS 




 Study the mitochondrial events that ensues following cytosolic 
acidification to test the effect of hTERT expression in the engagement 
of cell death pathways 
 To evaluate the influence of hTERT on cell viability following 
































MATERIALS AND METHODS 
1. Cell Lines and Plasmids 
The human cervical cancer cell line HeLa and the human neuroblastoma cell line SH-
SY5Y were purchased from American Type Culture Collection (ATCC; Rockville 
MD). The plasmids pBabe-Neo and pBabe-Neo-hTERT were a generous donation by 
Dr. Fabrizio d’Adda di Fagagna, Ph.D. Principal Investigator, IFOM Foundation – 
The FIRC Institute of Molecular Oncology Foundation, Milan, Italy. 
2. Antibodies 
For Western hybridization:  
Mouse Monoclonal β-Actin, GAPDH (Sigma Aldrich, St Louis, MO, USA) 
Mouse Monoclonal GCLC (Abnova, Taipei city, Taiwan) 
Mouse Monoclonal VDAC1 (Calbiochem, San Diego USA) 
Mouse Monoclonal anti-poly (ADP-ribose) polymerase (BD Pharmingen, San Diego, 
CA, USA) 
Mouse Monoclonal Cyt. C, Mn SOD (Cell Signaling Technology, Inc. Danvers, MA)  
Rabbit monoclonal hTERT (Epitomics, Burlingame, California, U.S.A.) 
Rabbit monoclonal Cu/Zn SOD (Signaling Technology, Inc. Danvers, MA) 
Rabbit polyclonal Anti Bax N20, SMAC (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) 
Rabbit polyclonal Catalase (Calbiochem, San Diego, CA, USA) 
Rabbit polyclonal Prx I, II, III, SO3, Trx I (Lab Frontier, Korea, Seoul) 





Goat Anti-Rabbit IgG HRP conjugated secondary antibody (Pierce Chemical Co. 
Rockford, IL) 
3. Chemicals  
From Sigma Aldrich Co (St Louis, MO) the following commonly used reagents were 
purchased: Hydrogen Peroxide, Absolute Ethanol, β-mercaptoethanol, Bromophenol 
Blue, BSA, DMSO, Tween 20, EDTA, and DTT. 
From NUMI Media Preparation Facility (NUS, Singapore), the following items were 
purchased: 10x PBS, 10x SDS, Tris HCl buffer (pH 7.4) 
4. Cell culture 
All the cell lines used were grown and passaged in a humidified incubator at 37°C 
with 5% CO2. HeLa cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Hyclone, Logan, Utah, USA) supplemented with 1% L-glutamine, 1% 
streptomycin-penicillin (Gemini Bio-Products) (v/v), 10% FBS (Hyclone, Irvine, CA) 
(v/v) 1% L- Glutamine and 1% streptomycin-penicillin. HeLa cells were stably 
transfected with pBabe-Neo (Neo cells) or pBabe-Neo-hTERT (HT1 cells) plasmids 
and were cultured in cultured in DMEM supplemented with 1% L- Glutamine and 1% 
streptomycin-penicillin and maintained in 500μg/ml of G418 disulphate salt solution 
(Roche Diagnostics Corporation, Inc, USA). SH-SY5Y cells were cultured in RPMI-
1640 (Hyclone, Logan, Utah, USA) supplemented with 1% L-glutamine, 1% 
streptomycin-penicillin (v/v), 10% FBS (Hyclone, Irvine, CA) (v/v) 1% L- Glutamine 
and 1% streptomycin-penicillin.  Cells plated for assays were plated in G418-free 




5. Plasmid Information 
 
                             
The plasmid information for p-Babe-Neo (Addgene plasmid 1767) and p-Babe-Neo-




restriction enzymes, namely Ecor I and Sal I and primer sequences (see below) for 
plasmid verification were also obtained from the Addgene website. 
pBABE 3' ACCCTAACTGACACACATTCC reverse primer
pBABE 5' CTTTATCCAGCCCTCAC forward primer 
6. Amplification and purification of Plasmids 
Amplification of plasmids was carried out by using NucleobondTM DNA purification 
kit according to the manufacturer’s manual. Briefly, 100 μl of Escherichia coli 
(E.coli) competent cells were incubated with 100 ng of each plasmid at 4 °C for 3 min 
before being subjected to heat-shock treatment for 1 min at 37 °C, then being 
incubated on ice for 5 mins. The cells were then added to 900 μl of super optimal 
catabolite repression (SOC) buffer and the mixture were incubated at 200 rpm for 30 
mins in a 37 °C bacterial incubator with 5% CO2. Next, 100 μl of the mixture were 
plated on lysogeny broth (LB) plates which were prepared with Ampicillin antibiotics, 
before being incubated at 37 °C for 16 hours.  
A mini culture was made by selecting a single cell colony from the agar plate and 
incubating it with 4 ml of LB medium containing ampicillin antibiotic for 16 hours at 
37 °C in 5% CO2. Following which, the mini culture was transferred to a maxi culture 
by adding 1 ml of mini culture to 250 ml of LB medium containing ampicillin 
antibiotic and the mixture broth was incubated for 16 hours at 37 °C. After, 
incubation, the maxi culture was centrifuged at 2500 rpm for 30 min at 4 °C. The E. 
coli pellet was resuspended with 10 ml S1 buffer provided by the manufacturer and 
then lysed with 10 ml S2 buffer. The resultant supernatant was incubated for 10 min 
at 4 °C before being neutralized with 10 ml S3 buffer and subjected to centrifugation 




NucleobondTM ion-exchange column which was pre-equilibrated with 5 ml N2 buffer. 
After the supernatant had passed through, 12 ml of N3 buffer was run through twice 
to wash the column. The plasmids were then eluted with 12 ml of N5 buffer followed 
by precipitation with 8.4 ml of isopropanol before being centrifuged at 11,500 rpm for 
30 mins at 4 °C.  
For the purification process, the plasmids were resuspended with 1:10 volume 5 M 
NaCl and 2 volume 95% vol/vol ethanol before being transferred to -80 °C for 30 
mins. After incubation, the mixture was centrifuged at 14,000 rpm for 30 mins at 4 °C 
and the resulting pellet was washed with 70% vol/vol ethanol twice. The pellet was 
allowed to be air-dried before it was resuspended in 100 μl of sterile RNAse free 
water.  
Amplification and verification of pBabe-neo and pBabe-neo-hTERT plasmids 
4 colonies were selected from the agar plates streaked with pBabe-neo-hTERT 
(pNT1-4) transformed DH5α E Coli cells. 3 colonies were selected from agar plates 
streaked with pBabe-neo (pN1-3) transformed DH5α E Coli cells. After the colonies 
were selected, minicultures were prepared and mini preps were performed to obtain 
the amplified plasmids. These plasmids were restricted using the restriction enzymes 
EcoRI and SalI. The restricted fragments were run on an agarose gel to check if the 
restriction fragments (Figure 12A) matched the expected sizes (Figure 12B). The 
minicultures which contained successfully transformed bacteria were then used to 
prepare glycerol stock for future use. Maxi culture was also prepared from these 
selected minicultures following which maxi prep was performed to obtain purified 
plasmids as described in the Materials and Methods.  The plasmids were next 










Size of hTERT 
insert  
Size/bp  5330  8830  3500  
  
Figure 12: Verification of plasmids. The plasmids were restricted using the 
restriction enzymes EcoRI and SalI. The restricted fragments were run on an agarose 
gel (A) to verify if the restriction fragments matched the expected size (B).  
7. Transient transfection 
Transient transfection of HeLa cells was performed using the SuperFect 
Transfection Reagents from QIAGEN GmbH (Germany). 4g of the pBabe-Neo 
(empty vector) or pBabe-hTERT-Neo was added to 24l of the SuperFect 
Transfection Reagent and transfection was carried out as recommended by the vendor. 
hTERT expression was detected from the cell lysates at the various post-transfection 




antibody at 1:1000 dilution (Epitomics, Burlingame, USA) and a secondary HRP-
conjugated goat anti-rabbit IgG at 1:1500 dilution (Pierce, IL, USA).  
8. Generation of Stable clones 
HeLa cells were transfected with 4g of pBabe-hTERT-Neo or pBabe-Neo vectors. 
Based on dose response experiments 600ug/ml of Geneticin (G418) could completely 
kill untransfected HeLa cells. Thus, this dose was used to supplement the medium 
after 72 hours of transfection. After three weeks the few surviving colonies of cells in 
the Neo and hTERT transfected plates were pooled respectively together and these 
two heterogenous populations were grown in medium supplemented with 600ug/ml 
G418. After a month of continuous culture, these cell lines were genotyped to confirm 
the overexpression of hTERT as compared to the control vector population.    
9. Silencing 
Cells of 40% confluency were transfected with ON-TARGET plus SMARTpool 
human hTERT siRNAs (small interfering RNA) (Dharmacon Inc, Chicago IL) siRNA 
(50nM) in Optimem1TM (Invitrogen Corporation) without serum.  Dharmafect1 were 
used according to manufacturer’s instructions for transient knockdown of hTERT.  
Briefly, 4 μl Dharmafect1 reagents were added to 200 μl of Optimem1 and the 
mixture (A) was vortexed for 10 seconds before being incubated for 5 min at 37 °C. 
In another tube, 50 nM of siRNA were resuspended in 200 μl of Optimem1 (B). 
Similarly, this mixture was also vortexed and incubated for 5 min at 37 °C, before 
being added drop-wise to the former tube. After mixing, 400 μl of the transfection 
mix (A and B) were added drop-wise to the respective wells.  Following siRNA 




after transfection the cells were analyzed as required and protein expression was 
assessed by Western blotting. 
10. Crystal violet cell viability assay 
Cell viability was assayed using crystal violet staining. Crystal violet was prepared as 
0.75% solution in 50% EtOH to distilled water with 1.75% formaldehyde and 0.25% 
NaCl and stored at room temperature. Following treatment the cells were washed with 
1x PBS and incubated with 0.5ml of crystal violet for 15 min. Cells were then washed 
with 1x PBS to remove excess crystal violet solution and air dried. The crystals on the 
plate were then dissolved in 1% SDS. Viability was determined by absorbance at 
595nm wavelength with the microplate reader (Tecan Spectrofluoroplus, Tecan Ltd, 
Maennedorf, Switzerland)  
11. Analysis of DNA fragmentation by Propidium Iodide Staining 
The DNA intercalating probe propidium iodide (Sigma Aldrich Co, St Louis, MO) 
was used to determine DNA fragmentation. Following treatment, the cells were 
washed and resuspended in 1ml of 1x PBS and immediately fixed with 70% ethanol : 
water. The cells were vortexed while adding ethanol to prevent clumping. The cells 
were then incubated for 15 min at 4 °C before they were washed once with 1x PBS 
and resuspended in 500µl PI: RNAase solution for 30min. Stained cells were then 
analyzed by flow cytometry with excitation and emission wavelengths at 488nm and 
610nm respectively. 10000 events were collected per sample to obtain the required 
data. PI binds to the DNA by intercalating between the bases with a stoichiometry of 
5bases per dye. Upon DNA binding, the fluorescence is enhanced and thus the 




analysis, four peaks (sub G-1. G1. S and G2M) populations can be detected with the 
apoptotic fragments of DNA marked by the sub G-1 population 
12. Colony forming 
HeLa cells were treated with H2O2 and C1 for 12 hrs following which they were 
washed with 1x PBS, trypsinized, counted and 5000 – 10000 cells were then replated 
into 100mm culture dishes and left to form colonies over a period of 10 to 14 days in 
a humidified incubator at 37°C with 5% CO2. Culture dishes were then stained with 
crystal violet. The number of colonies formed was also manually scored using a 1 cm 
by 1 cm grid system.  
13. Assessment of intracellular ROS levels via CM-H2DCFDA staining 
Treated or untreated cells were washed with 1x PBS and loaded with 5-(and-6)-
chloromethyl-2.,7-dichlorofluorescin diacetate (CM-H2DCFDA; Molecular Probes, 
Eugene, OR; 5 µM) at 37ºC for 15 minutes. Following this, the cells were washed 
with 1x PBS and analyzed by flow cytometry (Coulter EPICS Elite ESP; Beckman 
Coulter, Fullerton, CA or BD CellQuest Pro version 5.2) using an excitation 
wavelength of 488nm and emission wavelength of 525nm. At least 10000 events were 
analyzed using the WinMDI (Windows multiple document interface for flow 
cytometry) software (Beckman Coulter Inc., Sunnyvale, CA). 
14. Assessment of Mitochondrial O2- levels via MitoSox Red staining 
MitoSox Red (Invitrogen, CA, USA), is a live-cell permeable dye with hydroethidine 
(HE) covalently linked to a triphosphonium cation through a hexyl carbon chain. The 
positive charge on the phosphonium group enables this dye to be selectively targeted 




response to a negative membrane potential (Robinson et al., 2006; Ross et al., 2005). 
The dye exhibits red fluorescence once it is oxidized by superoxide (O2.-) After 15 
min incubation with MitoSox Red cells were washed twice with 1x PBS and 
immediately analyzed an Epic Profile flow cytometer with excitation set at 510 nm. 
Data were analyzed for 10000 events using the WinMDI software. 
15. Measurement of Mitochondrial Membrane Potential using DIOC6 
5,3,3’-dihexyloxacarbocyanine iodide (DIOC6(3)) (Sigma Aldrich Co, St Louise, 
MO)  is a cell permeant, hydrophobic dye that is selective for mitochondria at low 
concentrations. The cationic dye is depolarized by the negatively charged 
mitochondria to yield green fluorescence. The potential sensitive probe (DIOC6(3)) 
was used to analyze mitochondrial membrane transmembrane potential (Δψm). 
Following treatment, cells were loaded with 5uM DIOC6(3) and analyzed by flow 
cytometry with excitation and emission wavelength at 488 and 525nm respectively.  
16. Assessment of intracellular reduced / oxidised glutathione levels 
The glutathione assay was performed and modified from the protocol by Hissin and 
Hilf et al. [35] In conducting the GSH assay, a kit was not used and, thus, this 
protocol required optimisation. From the protocol optimisation procedure, it was 
learnt that slight changes in pH of the assay buffer and amounts of trichloroacetic acid 
(TCA) were important factors in determining the GSH levels in cells, as the use of an 
assay buffer with a pH lower that 8 resulted in most unsatisfactory results.  
Reduced and oxidised glutathione (GSH and GSSG) and N-ethylamide (NEM) were 
obtained from Sigma Aldrich Co (St Louise, MO). 0.18million cells were seeded over 




once with ice cold phosphate buffered saline (PBS). 360μl of ice-cold TCA (6.5%) 
was added to each well and the plates were left in 4°C for 10 minutes.  
o –Phthaladehyde (OPT) (Sigma Aldrich Co, St Louise, MO) solution was prepared 
fresh in reagent-grade absolute methanol (Merck Inc, White house Station, NJ) just 
prior to use. 10mM N-ethylamide (NEM) solution (Sigma Aldrich Co, St Louise, 
MO) was prepared fresh each time in deionized water.   
Buffer 1 was prepared with 0.1M KH2PO4 and 0.005M EDTA in 100ml deionized 
water (pH8 with 1M NaOH) and kept at 4°C until used. Buffer 2 was prepared fresh 
every time with 15ml of Buffer 1 and 163.5μl 1M NaOH. For determination of GSH 
levels, the final assay mixture was prepared fresh every time with 7.4ml of Buffer 2 
and 400μl OPT containing 400μg OPT. The reaction mixture for the GSSG assay was 
made fresh every time with 7.4ml of 0.1M NaOH and 400μl of OPT.  
GSH Assay 
185μl of the final assay mixture for GSH assay was added into each well of the 96-
well plate (NUNC). 7.5μl of the GSH standards or samples were added into each well. 
The plate was incubated in the dark at room temperature for 20 minutes. 
GSSG Assay 
0.04M of NEM was added to a 0.2ml portion of the sample and incubated at room 
temperature for 30 minutes. 185μl of the reaction mixture for GSSG assay was added 
into each well of a 96-well plate (NUNC). 7.5μl of the GSSG standards or samples 
that were incubated with NEM were added into each well. The plate was incubated in 




plates were read for fluorescence at 350nm excitation and 420nm emission using the 
POLARstar OPTIMA multidetection microplate reader (BMG Labtech).  
GSH and GSSG stock solution was prepared with TCA to 30nmol/ml. All solutions 
were kept on ice throughout the experiment. 
Measurement of Protein concentrations for Glutathione assay  
600μl of 1M NaOH was added to the cells after treatment with TCA. The cells were 
then detached and the supernatant was centrifuged at 12500rpm at 4°C for 5 minutes. 
1.5μl of the supernatant were added to 150μl of Coomassie Brilliant Blue G-250 into 
a 96-well plate (NUNC). The plate was read for absorbance at 595nm using the 
microplate reader (Tecan Spectrofluoroplus, Tecan Ltd, Maennedorf, Switzerland)  
Table 1: Standards for GSH and GSSG assay 
GSH or GSSG standard 
(nmol/ml) 
Volume of stock solution 
(μl) 
Volume of TCA (6.5%) 
(μl) 
30 100 0 
20 66.6 33.3 
15 50 50 
10 33.3 66.6 
7.5 25 75 
5 16.7 83.3 
2.5 8.3 91.7 





17. Glutathione Peroxidase Assay 
This assay is based on the oxidation of glutathione (GSH) to oxidized glutathione 
(GSSG) catalysed by the Glutathione Peroxidase (GPx) assay, which is then coupled 
to the recycling of GSSG back to GSH using Glutathione Reductase and NADPH (β-
Nicotinamide Adenine Dinucleotide Phosphate, Reduced) (Sigma Aldrich Co, St 
Louise, MO). The decrease in NADPH absorbance is measured at 340nm during the 
oxidation of NADPH to NADP+ where GPx is the limiting agent in this reaction. 
Cumene hydroperoxide (Sigma Aldrich Co, St Louise, MO) was used as the substrate 
to measure the total GPx activity in the assay.  
20 x 106 cells were harvested and washed with ice cold PBS and homogenized in cold 
sample buffer (50mM Tris-HCL, pH 7.6, containing 5mM EDTA, 1mM DTT and 
1mg/ml BSA). After incubation in ice for half an hour the samples were centrifuged at 
10000g for 15min at 4°C and protein concentrations were assayed using the Bradford 
assay. To perform the assay, a 96well plate was utilized. In the sample wells and 
background non enzymatic wells 100 µl Assay Buffer (50mM Tris-HCL, pH 7.6, 
containing 5mM EDTA) was first added. Next 50 µl of co substrate buffer (at a final 
concentration of 0.2mM NADPH, 2mM GSH, 1unit/ml Glutathione Reductase) were 
added to all the wells. 20µl of sample at a concentration of 100µg were added to the 
sample wells while 20µl of sample buffer were added to the background wells. The 
reaction was then initiated with 20µl of cumene hydroperoxide with a final 
concentration of 0.7mM.  The plate was carefully shaked for a few seconds before the 
absorbance was read at 340nm with the microplate reader (Tecan Spectrofluoroplus, 




The activity was calculated by first determining the change in absorbance per minute 
(ΔA340) per minute. 
ΔA340 = A340 (time 2) - A340 (time 1) 
  Time 2(min) – Time 1(min) 
Next the rate of ΔA340/min for the background wells was determined in a similar 
manner and subtracted from the rate for the sample wells.  
The following formula was then used to calculate the GPx activity. The reaction rate 
at 340nm can be determined by using the NADPH extinction coefficient of 
0.00373µM -1.  
Unit definition:1 unit of GPx will cause the formation of 1.0µmol of NADP+ from 
NADPH per minute at 25°C in a coupled reaction in the presence of reduced 
glutathione, GR, and cumene hydroperoxide. 
GPx activity = ΔA340/min x 0.19ml x sample dilution     = nmol/min/ml 
          0.00373µM-1 x 0.02ml 
18. Glutathione Reductase Assay 
The assay is based on the reduction of glutathione (GSSG) by NADPH in the 
presence of glutathione reductase. The decrease in NADPH absorbance was measured 
at 340nm during the oxidation of NADPH to NADP+.  
10 x 106 cells were harvested and washed with ice cold PBS and homogenized in cold 
sample buffer (50mM KH2PO4 , pH 7.5 containing 1mM EDTA and 1mg/ml BSA). 
After incubation in ice for half an hour the samples were centrifuged at 10000g for 
15min at 4°C and protein concentrations were assayed using the Bradford assay. To 




non enzymatic wells 100 µl Assay Buffer (potassium phosphate, pH 7.5 containing 
1mM EDTA) were first added. Following this, 20µl of GSSG was added to yield a 
final concentration of 1mM. Next 20µl of sample was added to the sample wells. And 
20µl of sample buffer were added to the background wells. The reaction was finally 
initiated with 50µl of NADPH with a final concentration of 0.1mM. Next, the plate 
was carefully shaked for a few seconds before the absorbance was read at 340nm with 
the microplate reader (Tecan Spectrofluoroplus, Tecan Ltd, Maennedorf, Switzerland) 
once every minute for 15 min.  
And the activity was calculated by first determining the change in absorbance per 
minute (ΔA340) per minute. 
ΔA340 = A340 (time 2) - A340 (time 1) 
  Time 2(min) – Time 1(min) 
Next the rate of ΔA340/min for the background wells was determined in a similar 
manner and subtracted from the rate for the sample wells.  
The following formula was then used to calculate the GPx activity. The reaction rate 
at 340nm can be determined by using the NADPH extinction coefficient of 
0.00373µM -1. Unit definition:1 unit of GPx will cause the formation of 1.0µmol of 
NADP+ from NADPH per minute at 25°C. 
GR activity = ΔA340/min x 0.19ml x sample dilution     = nmol/min/ml 
          0.00373µM-1 x 0.02ml 
19. Assessment of Telomerase Activity using TRAP Assay 
Telomerase activity detection was performed with the commercially available 




were done according to the manufacturer’s instructions. Briefly, total protein was 
extracted using CHAPS lysis buffer provided, then 1.5 µg protein treated with 1 ul/ml 
RNase inhibitor was used to perform PCR reaction. During the TRAPEZE® XL 
assay, telomerase from cell/tissue extract adds a number of telomeric repeats onto the 
3’ end of the TS oligonucleotide. The extended products were amplified using PCR 
with the TS and flourescein-labelled Amplifluor® reverse primer. A second 
sulforhodamine-labeled Amplifluor® primer, K2, amplified an internal PCR control 
producing red fluorescence. Telomerase activity was determined by calculating the 
ratio of green : red fluorescence and extrapolating the quantity of telomerase units 
from a control standard curve. Controls for this experiment was telomerase-positive 
cell lysate, TSR 8 for generating standard curve, Taq-negative control, CHAPS-only 
control, heat treated sample, and Sulforhodamine house-keeping control. Telomerase 
activity was measured by spectroflurometer (GENios Plus, Tecan Group Ltd., 
Maennedorf, Switzerland) by measuring the relative fluorescence emission of 
flourescein at 535nm following an excitation of 405nm and Sulforhodamine at 
excitation 590nm and emission 635nm. 
20. Assessment of Cytochrome c Oxidase Activity 
 Cells were dissolved in 2ml of COX buffer (250mM sucrose, 2mM HEPES and 
0.1mM EGTA at pH 7.4) before being centrifuged at 330g for 10mins at 4C. The 
cells were then resuspended with 1ml of COX buffer and incubated for 10mins at 4C 
before being subjected to homogenization for 10 passages and the cell lysate was spun 
at 600g for 10mins at 4C. The supernatant was then centrifuged at 14400g for 
10mins at 4C. The resultant pellet is the purified mitochondria fraction, containing 




pH 7.2 and incubated at RT for 3mins. COX activity was measured by monitoring the 
oxidation of reduced Cyt. C by spectrophotometric analysis at 550nm for 2mins at 
37C using BioSpec-1601 spectrophotometer (Shimadzu, Japan). COX activity was 
determined by measuring the decrease in absorbance of ferrocytochrome c caused by 
its oxidation to ferricytochrome c by COX.     
21. Detection of hTERT Gene Expression by RT-PCR 
Total RNA was extracted using RNAeasy kit (Qiagen, 74104) according to the 
manufacturer’s instructions. RNA yield and purity was assessed by Nanodrop (ND-
1000 Spectrophotometer). Quantitative detections of hTERT mRNA were performed 
with the commercially available LightCycler TeloTAGGG hTERT Quantification Kit 
(Roche Diagnostics, 3012344) for real time PCR. Briefly, this kit utilizes the 
telomerase enzyme present in the cell lysate to add a number of telomeric repeats 
(GGTTAG) to a substrate oligonucleotide in the reaction mixture. Subsequently, the 
extended products were amplified by a Taq polymerase using flourescein labelled 
reverse primers which emit a florescence when they are incorporated into the PCR 
products. Thus with increased telomerase activity, there will be more extended 
products available for PCR amplification and, hence, greater incorporation of the 
reverse primers and increased florescence emission.  
22. Determination of Protein Expression by Western Blot Analysis 
Whole cell protein extracts were isolated using 1x RIPA lysis buffer (50mM Tris-
HCl, pH 7.4, 150mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1mM EDTA) and 
protease inhibitors (Calbiochem, San Diego, CA). Next the protein concentrations 




IL). Briefly, 1.5μl of the supernatant were added to 150μl of Coomassie Brilliant Blue 
G-250 into a 96-well plate (NUNC). The plate was read for absorbance at 595nm 
using the microplate reader (Tecan Spectrofluoroplus, Tecan Ltd, Maennedorf, 
Switzerland). After determining the protein concentrations, equal amounts of protein 
from the total cell lysates (30 to 120μg/lane) were mixed with 5x Laemelli loading 
dyes and boiled for 5 min. The samples were then separated by sodium dodecyl 
sulfate (10%, 12% or 15%) polyacrylamide gel electrophoresis gels (SDS-PAGE; 
BioRad Laboratories) and transferred to PVDF membranes (BioRad Laboratories) 
using wet transfer (BioRad Laboratories). The membrane was then blocked with 5% 
(w/v) fat-free milk in Tris-buffered saline containing 0.05% (v/v) Tween 20 (TBST) 
for 1 hr. After three washes with TBST to remove excess milk, the membrane was 
probed for the protein of interest with the relevant primary antibody in 5% (w/v) BSA 
in TBST at 4°C overnight. The membrane was subsequently subjected to three washes 
with TBST to remove unbound primary antibody and probed again with the 
appropriate HRP-conjugated secondary antibody in TBST containing 1% (w/v) fat-
free milk for 1 hr at room temperature. After three washes with TBST to remove any 
excess unbound secondary antibody, the desired probed proteins were next detected 
with Kodak Biomax MR X-ray film (Eastman Kodak Co., Rochestor NY) by 
enhanced chemiluminescence using the Super Signal Chemiluminescent Substrate 
(Pierce, Rockford, IL, USA).  
22.1 Buffers used for Western Blot Analysis 
Resolving gel preparation (0.375M Tris, pH 8.8) 




dH2O (ml) 2.35 3.35 4.02 4.85 5.68 
1.5M Tris pH 8.8 (ml) 2.5 2.5 2.5 2.5 2.5 
10%SDS 100 µl 100 µl 100 µl 100 µl 100 µl 
30% Acrylamide/Bis (ml) 5 4 3.33 2.5 1.67 
10% APS 50 µl 50 µl 50 µl 50 µl 50 µl 
TEMED 5 µl 5 µl 5 µl 5 µl 5 µl 
Total volume 10 10 10 10 10 
Linear separating range (KD) 12-43  16-68 36-94 57-212 
Stacking gel preparation: 4% gel, 0.125M Tris-Hcl, pH 6.8 
  Total 10ml 
  dH2O (ml) 7.29 
  1.0 M Tris pH 6.8 (ml) 1.25 
  10%SDS 100 µl  
  30% Acrylamide/Bis (ml) 1.3 
  10% APS 50 µl 
  TEMED 5 µl  
  Total volume 10 ml 
 
Running Buffer for SDS-Page gel: 10X (2L) 
Tris-base 60g, glycine 288g, SDS 20g, top to 2L with dH2O. 
Transfer Buffer for Western blot: 1X (5L) 
Tris-base 12.1g, glycine 57.84g, methanol 1L, top to 5L with dH2O. 




100 mM Tris-HCL pH 6.8, 3.1 ml (1M), SDS 1g (10%), glycerol 2 ml (20%), β-
Mercaptoethanol 2.5 ml (25%), Bromophenol Blue 0.01g (0.1%), top to 10 ml with 
2.4 ml distilled H2O. 
Membrane Stripping Buffer: 1X (100ml) 
1 M Tris-HCl, 6.25 ml pH 6.8, β-Mercaptoethanol 714 µl, 10% SDS 20ml , top to 
100ml with 66.8ml of distilled H2O 
TBS 
TBS was prepared as 500 ml 1 M Tris HCl (pH 7.4) with 87.6 g of NaCl in 10L of 
distilled water and stored at room temperature. 
TBST 
TBST was prepared as 2 L TBS with 2 ml of Tween-20 and stored at room 
temperature. 
23. Isolation of mitochondrial and cytosolic fractions 
Cells were harvested and washed once with ice-cold 1x PBS and spun down by 
centrifugation at 1200rpm for 5mins at 4C. The pellet was resuspended in 10 
volumes of extraction buffer (200mM mannitol, 68mM sucrose, 50mM Pipes-KOH 
pH 7.4, 50mM KCL, 5mM EGTA, 2mM MgCl2, 1mM DTT), containing various 
protease inhibitors (1mM PMSF, 10g/ml aprotinin, 20g/ml pepstatin A and 
10g/ml leupeptin) and incubated on ice for 20mins. After incubation, the cells were 
homogenized with a dounce homogenizer and passaged for 20 strokes before being 
centrifuged at 300g for 10mins at 4C. Following which, the supernatant was 
centrifuged again at 12000g for 15mins at 4C. The pellet contains the intact 




buffer and the supernatants are used as cytosolic fractions. The fractions were then 
subjected to SDS-PAGE and Western blotting as described in Materials & Methods. 
24.  Isolation of nuclear and cytosolic fractions 
Cells were harvested and washed once with ice-cold 1x PBS and spun down by 
centrifugation at 1500g for 3 min. The pellet was resuspended in 400 μl of Nuclear 
Buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 
mM DTT ) containing the protease inhibitor (0.5 mM of PMSF) and incubated on ice 
for 15 min. Following incubation, 25 μl of NP-40 were added to the cell suspension 
and vigorous vortexing was carried out for 10 sec. The cell suspension was then 
centrifuged at 14,000 rpm for 30 sec at 4 °C. The supernatant (cytosolic fraction) was 
then transferred to a clear centrifuge tube and stored at -80 °C. The pellet containing 
nuclear fraction was resuspended with 50 μl of ice cold Buffer C (20 mM HEPES pH 
7.9, 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) containing a cocktail of 
protease inhibitors (1mM PMSF, 10g/ml aprotinin, 20g/ml pepstatin A and 
10g/ml leupeptin) and incubated for 15 min at 4 °C before being kept at -80 °C. The 
fractions were then subjected to SDS-PAGE and Western blotting as described in 
Materials & Methods. 
25. Measurement of Protein concentrations (Bradford Assay) 
600μl of 1M NaOH were added to the cells after treatment with TCA. The cells were 
then detached and the supernatant was centrifuged at 12500rpm at 4°C for 5 minutes. 
1.5μl of the supernatant were added to 150μl of Coomassie Brilliant Blue G-250 into 
a 96-well plate (NUNC). The plate was read for absorbance at 595nm using the 




26.  Statistical Analysis 
All experiments were performed at least three times for statistical significance. 
Numerical data were expressed as mean + SD. Statistical analysis was performed 
using the paired Student’s t-test considering the variances unequal. P values < 0.05 

















1 hTERT AND ROS CAN CROSS REGULATE EACH OTHER 
1.1 hTERT expression and activity is regulated by H2O2 in a dose dependant 
manner 
In order to study the effect of oxidative stress on hTERT, HeLa cells were exposed to 
a bolus treatment of H2O2 in a dose dependant manner for 12 hrs. The hTERT protein 
levels decreased when exposed to higher concentrations of H2O2 (>150 μM) (Figure 
13A). This finding was consistent with reports by other groups that showed high 
apoptotic concentrations of ROS can lead to the suppression of hTERT expression 
(Chou et al., 2005; Chou et al., 2001).  
Higher concentrations of H2O2 (> 200 μM) showed a decrease in telomerase activity. 
However at lower doses (< 80 μM) a linear drop in telomerase activity was not 
observed with an increasing concentration of H2O2. Instead there was an increase in 
telomerase activity up to 80 μM of H2O2 (Figure 13B). This suggests that ROS might 
have a dual effect on hTERT activity depending on the concentration used. The 
decrease in telomerase activity at higher concentrations could have been due to the 
down regulation of hTERT expression. However, at lower concentrations, no increase 
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Figure 13: Effect of H2O2 on hTERT expression and activity. HeLa cells were 
treated for 12 hrs with H2O2 in a dose dependant manner. The cells were harvested 
and whole cell lysates were then prepared and subjected to Western immunoblot 
analyses of hTERT as described under materials and methods. Beta actin was used as 
a loading control.  (A). In parallel experiments, cell lysates were also subjected to 
TRAP analysis to measure the telomerase activity of the cells. Data shown are mean ± 














1.2 hTERT localization can be modulated by exposure to H2O2 
The localization of hTERT can largely influence its cellular functions. Acute 
oxidative stress has been shown to modulate hTERT localization in cells leading to 
nuclear export (Haendeler et al., 2003). To investigate how ROS can modulate 
intracellular localization, HeLa cells were treated with 300 μM of H2O2 from 0 to 4 
hrs (Figure 14). Following treatment, the cells were fractionated and the nuclear and 
cytosolic fractions were analyzed by Western blot. Up to 0.5hr after treatment with 
H2O2, hTERT is mainly localized at the nucleus. From 2 hrs on, a decrease in the 
hTERT levels in the nuclear fraction and a subsequent increase in the cytosolic 
fractions can be observed. This suggests that hTERT is being translocated from the 
nucleus into the cytosol. This result corroborates findings by Haendeler et al 







Figure 14: hTERT translocation upon treatment with H2O2.  HeLa cells were 
treated with 300 µM H2O2 from 0 to 4 hours. The cells were then harvested and 
fractionated to obtain the cytosolic and nuclear fractions. The samples were subjected 
to Western blot analysis of hTERT. Beta actin was used as a cytosolic loading control 



















1.3 Transient hTERT overexpression can modulate intracellular ROS levels 
To address the effect of hTERT expression on ROS, hTERT was transiently 
expressed in HeLa cells which have a moderate background expression of hTERT. 
Thus HeLa cells were transiently transfected with 4 μg of pBabe-Neo or pBabe-Neo-
hTERT plasmids as described in Materials and Methods. After 72 hrs, the cells were 
harvested for Western blot or stained with CM-H2DCFDA, a redox sensitive dye, 
which can be oxidized by ROS. The oxidized product can be detected by the shift in 
fluorescence by fluorescent-activated cell sorting (FACS) using a flow cytometer. 
Overexpression of hTERT was analyzed by Western blot. (Figure 15A). In the HeLa 
cells with a transient overexpression of hTERT, lowered basal intracellular ROS 
levels were observed. This was indicated by the leftward shift in the histogram 
(Figure 15B) which reflects a drop in DCF florescence and hence a drop in 
intracellular ROS levels. The G-mean values of DCF florescence obtained from 3 
independent experiments were used to calculate the fold difference in ROS levels 
between control and hTERT overexpressing cells (Figure 14C). A significant 14% 
drop in intracellular ROS levels can be observed in hTERT overexpressing cells. 
Given that the mitochondrion is one of the key sources of ROS, mitochondrial ROS, 
specifically O2.-, levels were also assayed using Mitosox Red. This probe is cell 
permeant and relatively selective for the detection of mitochondrial superoxide in 
living cells. Once in the mitochondria, the dye is oxidized by superoxide. The 
oxidized product can be detected by a shift in the fluorescence by fluorescent-
activated cell sorting (FACS) using a flow cytometer. hTERT overexpressing cells 




transient hTERT overexpression lowers both basal mitochondrial ROS and total 
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Figure 15: Transient hTERT overexpression reduces basal intracellular ROS. 
HeLa cells were transiently transfected with pBabe-neo (Neo) or pBabe-neo-hTERT 
(hTERT). The cells were then harvested and Western blot was performed to assess 
overexpression of hTERT (A). Beta actin was used as a loading control. Intracellular 
reactive oxygen species was detected by flow cytometry using the probe CM-H2-
DCFDA (B). The average G-Mean ± SD values of 3 independent experiments are 






Figure 16: Transient hTERT overexpression reduces mitochondrial superoxide 
levels. HeLa cells were transiently transfected with pBabe-neo (Neo) or pBabe-neo-
hTERT. Mitochondrial superoxide levels were detected by flow cytometry using the 














1.4 Transient hTERT overexpression resists the increase in intracellular ROS 
levels following treatment with H2O2 
Since transient hTERT expression resulted in a decrease in basal levels of intracellular 
ROS it was of interest to investigate if hTERT overexpressing cells were also better 
able to cope with ROS triggers. It was hypothesized that an improved capacity to 
withstand oxidative insults would improve the survival capacity of these cells 
rendering them more resistant to oxidative stress. Thus HeLa cells were plated and 
transfected with the plasmids pBabe-neo (Neo) or pBabe-neo-hTERT (hTERT) as 
previously described for 72 hrs. Overexpression of hTERT was detected by Western 
blot. (Figure 16A) Following transfection, the cells were treated with 300 μM of H2O2 
for 3 hrs and the intracellular ROS levels were analyzed using CM-H2DCFDA (Figure 
17B and C). The cells transfected with the pBabe-neo plasmid showed a significant 
rightward shift in the DCF florescence indicative of higher intracellular ROS 
following treatment with H2O2. In contrast, the rightward shift in response to 
exogenous H2O2 was virtually completely inhibited in cells overexpressing hTERT. 
These data suggest that hTERT overexpression in cells is able to enhance their 
intracellular capacity to resist oxidative stress. The change in DCF florescence can 
also be read from the changes in the percentage of population that shifts into the right 
















Figure 17: Transient hTERT overexpressing cells display lower intracellular 
ROS when treated with H2O2. HeLa cells were transiently transfected with pBabe-
neo or pBabe-neo-hTERT as described in the Materials and Methods. Overexpression 
of hTERT was confirmed by Western blot analysis. (A) The cells were then exposed 
to 300 µM of H2O2 for 3 hrs. Intracellular reactive oxygen species was detected by 
flow cytometry using the probe CM-H2DCFDA. The histogram (A) and density plot  
(B) representations of the data shown above are a representative of 3 independent 
experiments and the percentage of the population in each quadrant in C is reflected at 












1.5 Transient hTERT overexpression in cells resists the increase in 
intracellular ROS following treatment with the ROS inducing compound C1. 
Having demonstrated that hTERT has an antagonistic effect on the intracellular ROS 
levels when treated with exogenous H2O2, we next asked whether a similar resistive 
response can be observed when cells are treated with anticancer drugs that induce 
intracellular H2O2 production. One such drug is C1, a small (Mr = 242) novel 
experimental anti cancer drug. This synthetic compound was first isolated and purified 
on photo-oxidation of merocyanine 540 (Pervaiz et al., 1999b). The chemical 
structure of this imidazole compound is N, N’-Dibutyl-thio-4, 5-imidazolindion 
(Pervaiz et al., 1999b). We have previously reported that C1 is able to induce 
intracellular ROS production, in particular H2O2, which can result in cellular 
acidification and cell death. In addition, our lab has also reported that exposure of 
cells to C1 can lead to a decrease in mitochondrial membrane potential followed by 
the release of Cyt. C and activation of the apoptotic pathway (Hirpara et al., 2001; 
Pervaiz et al., 1999b). 
Thus, Neo and hTERT cells were also treated with 100 μg/ml of C1 for 3 hrs 
following which their intracellular ROS levels were assayed using CM-H2DCFDA 
(Figure 18). Again, hTERT overexpressing cells displayed lower intracellular ROS 
levels as opposed to Neo cells following treatment with C1, and the reduced induction 
of intracellular ROS in the hTERT overexpressing cells was indicated by the 
decreased rightward shift in florescence as compared with Neo. This suggests that the 
hTERT overexpressing cells are not only resistant to exogenous H2O2 but are also 
able to resist drug induced intracellular ROS production as demonstrated here by 








Figure 18: Transient hTERT overexpressing cells display lower intracellular 
ROS when treated with C1. HeLa cells were transiently transfected with pBabe-neo 
or pBabe-neo-hTERT as described in the Materials and Methods. The cells were then 
exposed to 100 μg/ml of C1 for 3 hrs. Intracellular reactive oxygen species was 
detected by flow cytometry using the probe CM-H2DCFDA. The histogram (A) and 
density plot (B) representations of the data shown above are a representative of 2 
independent experiments and the percentage of the population in each quadrant in C is 




1.6 Generation of stable hTERT overexpressing cells and verification of 
hTERT expression and activity in stable clones 
Since the transient transfection model had already established a ground for the 
modulation of ROS by hTERT, stable cell lines expressing hTERT were generated to 
further these studies. HeLa cells were transfected with the pBabe-neo or pBabe-neo-
hTERT and selected with 600 μg/ml of G418 as described in the Materials and 
Methods. After selection and expansion, the cells were subsequently maintained in 
culture with 400 μg/ml of G418. The stably transfected cells were then assayed for 
hTERT expression at the RNA and protein levels and for telomerase activity to ensure 
that the stably transfected cells increased hTERT levels and activity as compared to 
the empty vector expressing cells. The levels were compared across 4 cell lines, the 
untransfected HeLa cells (ATCC), cells stably transfected with pBabe-neo (Neo) and 
pBabe-neo-hTERT (HT1 and HT2). Neo, HT1 and HT2 are independent 
heterogeneous populations of cells that were transfected with pBabe-neo or pBabe-
neo-hTERT. 
hTERT overexpressing HT1 and HT2 cells demonstrated higher hTERT RNA levels 
(Figure 19A), protein expression (Figure 19B) and telomerase activity (Figure 19C) 
compared to the Neo or ATCC cells. RNA levels were measured using a commercial 
kit that only detects and amplifies the full length hTERT mRNA. HT1 and HT2 cells 
showed a 30% to 50% increase in mRNA levels (Figure 19A). The telomerase activity 
was also about 2 to 3 fold higher in HT1 and HT2 cells as compared to Neo or 










Figure 19: Stable transfection of HeLa cells with pBabe-Neo and pBabe-hTERT-
Neo.  HeLa cells were transfected with pBabe-neo or pBabe-neo-hTERT as described 
in the Materials and Methods for the generation of stable clones. RT-PCR analyses of 
hTERT mRNA levels (A), Western blot analysis of hTERT protein expression (B), 
TRAP assay (C) to measure telomerase activity in the following cells: untransfected 
HeLa cells (ATCC), transfected with control pBabe-Neo vector, HeLa Neo (Neo), 2 
separate transfections with pBabe-hTERT-Neo, HeLa TERT 1 (HT1) and HeLa 
TERT 2 (HT2). Beta actin was used as a loading control. All data shown are mean ± 




1.7 Stable hTERT overexpression reduces basal intracellular ROS 
Given that transient hTERT expression resulted in reduced intracellular ROS, to test if 
a similar outcome could be obtained with stable hTERT overexpression, the basal 
intracellular ROS levels were assayed in Neo, HT1 and HT2 (Figure 20A) using the 
redox sensitive dye CM-H2DCFDA.  Compared to Neo, both HT1 and HT2 displayed 
reduced basal intracellular ROS levels. The G-mean values of DCF florescence 
obtained from 6 independent experiments were used to calculate the fold difference in 
ROS levels between Neo, HT1 and HT2 cells (Figure 20B). The results show a 
significant decrease in intracellular ROS levels in hTERT overexpressing cells. 
Indeed HT1 and HT2 cells show between 20% to 30% decrease in intracellular ROS 
levels as compared with Neo cells. 
 In addition the assessment of mitochondrial O2.- levels using the mitochondria 
specific probe MitoSox Red also displayed a 10% to 15% decrease in mitochondrial 
O2.- in HT1 and HT2 cells as compared with Neo cells (Figure 20C).  The G-mean 
values of the florescence obtained from 3 independent experiments in cells stained 
with MitoSox Red were used to calculate the fold difference in ROS levels between 
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Figure 20: Stable hTERT overexpression reduces basal intracellular ROS. Basal 
levels of intracellular reactive oxygen species were detected by flow cytometry in 
HeLa Neo, HT1 and HT2 cells using the probes DCHF-DA (A) and MitoSox Red (C). 
The average G-Mean values of the basal levels of intracellular ROS measured by 
DCHF-DA from 6 independent experiments (B) and MitoSox Red from 3 





1.8 Stable hTERT overexpression in cells blocks the increase in intracellular 
ROS following treatment with H2O2 or C1  
To reaffirm the results obtained with transient overexpression of hTERT, Neo and 
HT1 cells were treated with 300 μM H2O2 or 100 μg/ml of C1 for 3 hrs and assayed 
for intracellular ROS levels using CM-H2DCFDA. hTERT overexpressing HT1 cells 
displayed a decreased rightward shift in the DCF florescence following treatment with 
H2O2 (Figure 21A) or C1 (Figure 22A) as compared to the controls. The values at the 
corners of the density plots (Figure 21B and 22B) reflect the percentage population in 
that quadrant. The increase in DCF florescence can also be read from the changes in 
the percentage of population that shifts into the right quadrant following treatment 
with H2O2 or C1 in the Neo and HT1 cells. Indeed, treatment of Neo cells with H2O2 
or C1 results in about 30% and 50% increase in DCF florescence respectively as 
compared to the 10% and 20% increase observed in HT1 cells. This data corroborates 
earlier findings where an improved resistance to oxidative stress was observed in cells 








Figure 21: Stable hTERT overexpression in cells blocks the increase in 
intracellular ROS following treatment with H2O2. Neo and HT1 cells were 
exposed to 300µM of H2O2 (A) for 3 hrs. Intracellular reactive oxygen species was 
then detected by flow cytometry using the probe DCHF-DA. The histogram (A) and 









Figure 22: Cells with stable hTERT overexpression displays lower intracellular 
ROS when treated with C1. Neo and HT1 cells were exposed to 100 μg/ml C1 (A) 
for 3 hrs. Intracellular reactive oxygen species was then detected by flow cytometry 
using the probe DCHF-DA. The histogram (A) and density plot (B) representations of 





1.9 Stable hTERT overexpression alters hTERT expression and localization 
patterns 
Since hTERT overexpression was shown to resist an increase in cellular ROS levels, 
hTERT expression and localization were reinvestigated to test if hTERT 
overexpression might be able to influence hTERT expression and localization patterns 
following exposure to oxidative stress. Neo and HT1 cells were treated in a dose 
dependent manner from (0 to 300 μM) with H2O2 for 18hrs. Following treatment, the 
cells were harvested and the lysates were analyzed via Western blot and probed for 
hTERT. The results reflected a differential response between Neo and HT1 cells with 
H2O2 treatment. Neo cells showed a significant downregulation of hTERT expression 
when treated with bolus treatment of 300 μM H2O2, similar to that observed with 
treatment of HeLa cells with 300 μM H2O2. However, the sharp reduction in hTERT 
expression was not observed in HT1 cells (Figure 23A). 
Next, Neo and HT1 cells were treated with 300 μM H2O2 from 0 to 4 hrs and nuclear 
and cytosolic fractions isolated and analyzed by Western blotting. (Figure 23B). Since 
nuclear export of hTERT was previously observed after 2hrs of H2O2 treatment in 
HeLa cells, Neo and HT1 fractions were analyzed after 2hrs and 4hrs of treatment 
with H2O2. After 2 hrs of treatment with H2O2, more hTERT was observed in the 
cytosolic fractions of Neo cells as compared to HT1 cells suggesting that hTERT 










Figure 23: hTERT expression and localization in Neo and HT1 cells following 
H2O2 treatment. Neo and HT1 cells were treated for 18 hrs with H2O2 in a dose 
dependant manner. The cells were harvested and whole cell lysates were then 
prepared and subjected to Western immunoblot analyses of hTERT (A). In (B), Neo 
and HT1 cells treated from 0 to 4 hrs with 300 μM of H2O2. The cells were then 
harvested and fractionated to obtain the cytosolic and nuclear fractions. The samples 
were subjected to Western blot analysis of hTERT. Beta actin was used as a cytosolic 













Cumulatively, the data from the first section of the results has clearly demonstrated 
the cross regulation that exists between hTERT and ROS. In addition to the known 
effects of ROS on hTERT, the data have provided evidence to establish a role for 
hTERT in modulating the cellular redox status and has shown that hTERT 
overexpression can lower intracellular ROS levels and can block the increase in 
intracellular ROS levels following oxidative stress triggers such as H2O2 or C1. In 
addition, hTERT overexpression has also been shown to antagonize hTERT down 
regulation and its redistribution following oxidative stress. Given these findings, the 
natural question that would follow next would be how hTERT expression resists 
oxidative stress triggers and lowers intracellular ROS levels. Since the regulation of 
antioxidant levels or mitochondrial function are critical mechanisms via which cells 
modulate their intracellular redox balance, assessment of these parameters following 
hTERT overexpression was a logical step forward.  
2. UNRAVELING THE MECHANISMS BY WHICH hTERT 
EXPRESSION MODULATES INTRACELLULAR REDOX STATUS 
2.1 Assessment of critical antioxidant defences  
Given that there are numerous antioxidant defences present in a cell, in this thesis the 
focus was on the more critical and major intracellular antioxidant defences that could 
contribute to the reduction in mitochondrial and overall cellular ROS levels. Special 
attention was also given to antioxidants that target peroxides since H2O2 was a 
primary oxidative trigger that has been well resisted by hTERT expression. As such, 
the antioxidants such as superoxide dismutases, catalase and the thiol based 




2.1.1 Assessment of intracellular SOD and Catalase expression following 
hTERT overexpression 
Since mitochondrial superoxide levels were found to be lowered in hTERT 
overexpressing cells, Mn SOD levels were first assayed via Western blot analysis in 
HeLa ATCC, Neo, HT1 and HT2 cells. The results demonstrated upregulation of Mn 
SOD levels (Figure 24A). In order to corroborate the increase in Mn SOD expression 
that was observed with stable hTERT expression, transient transfections were 
performed with p-Babe-Neo and pBabe-Neo-hTERT for 72hrs following which the 
lysates were analyzed by Western blot analysis. Transient transfection with hTERT 
also displayed an increase in Mn SOD expression (Figure 24B).  
Given that catalase is one of the main peroxide quenchers in the cell, and the 
induction of H2O2 could be contained by hTERT overexpressing cells, the catalase 
levels were also analyzed. However, no difference in catalase levels was observed 
between the hTERT overexpressing cells and the control cells (Figure 24A). Since the 
mitochondrial SOD levels have been differentially regulated, the cytosolic SOD, 
which also plays a critical role in combating cellular ROS, was examined next. Unlike 
Mn SOD, no observable changes could be seen in Cu/Zn SOD levels (Figure 24A).  
Since Mn SOD expression was differentially regulated in Neo and HT1 cells we 
further assessed the SOD levels following treatment with 300 μM H2O2 (Figure 24C). 
No difference in Mn SOD expression following H2O2 treatment could be observed in 
Neo or HT1 cells. However, the SOD levels remained elevated in HT1 cells as 
compared with Neo cells. Even though catalase levels were the same in both cell lines 
it has been shown by other groups that exposure to ROS can modulate catalase levels 




HT1 cells were exposed to 300 μM H2O2 following which the cellular levels of 
catalase were assessed via Western blot. However, no significant difference in 
catalase expression was observed in both cell lines (Figure 24D). 
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Figure 24: Assessment of intracellular SOD and Catalase expression following 
hTERT overexpression and H2O2 treatment. HeLa ATCC, Neo, HT1 and HT2 
cells were harvested and whole cell lysates were prepared and subjected to Western 
immunoblot analysis of Mn SOD, Cu/Zn SOD and catalase (A). HeLa cells were also 
transiently transfected with hTERT for 72hrs following which the cellular Mn SOD 
levels were assayed via Western blot (B). Neo and HT1 cells were treated with 300 
μM H2O2 following which the lysates were subjected to Western blot analysis and 








2.1.2 Assessment of intracellular peroxiredoxins and thioredoxins levels 
following hTERT overexpression 
The thiol dependant peroxiredoxins (Prx) and thioredoxins (Trx) play a critical role in 
mopping up cellular peroxides. Though Prx I and Prx II are catalytically less efficient 
then GPx or catalase, they are more abundantly found in the cytosol and display a 
greater affinity to H2O2. This makes them prime candidates as regulators of H2O2 
signalling (Rhee et al., 2005a). Prx III is localized mainly to the mitochondria and 
serves as one of the main antioxidant defences against peroxides at the mitochondria 
which do not contain catalase. Trx are important in the regeneration of the Prx that 
have been oxidised to the sulfenic forms. Trx I has been extensively studied and it is 
localized to the nucleus and the cytosol and is critical in the regeneration of oxidised 
Prxs.  
Neo and HT1 cells were treated with 300 µM H2O2 from 0 to 8 hrs at two hourly 
intervals. Following treatment, whole cell lysates were prepared and the intracellular 
levels of Prx I, II, III and Trx I levels were assayed.  Total Prx I, II and III levels 
remained unchanged following treatment with H2O2 in Neo and HT1 cells. In 






Figure 25: Regulation of peroxiredoxins (Prx) and thioredoxin (Trx). Neo and 
HT1 cells were treated from 0 to 8 hrs with 300µM of H2O2. The cells were then 
harvested and whole cell lysates were prepared and subjected to Western blot analysis 
























2.1.3 hTERT overexpression increases the rate of regeneration of 
peroxiredoxins from the hyperoxidised forms 
By studying the rate at which these Prxs might be returned to their active state in 
cells, the cellular Prx activity can be indirectly assessed. In this regard, an antibody 
recently developed to detect the sulfonylated state of Prxs was used to probe this 
hyperoxidised form of Prx namely, Prx 1 SO3, Prx 2 SO3 and Prx 3 SO3. However, 
since Prx 1 and Prx 2 are of the same size it is usually seen as a single band. This has 
also been reported by another group using the same antibody (Woo et al., 2003b). 
Loading a lower lysate amount of 10 μg for Western blot analysis, also allowed for a 
better separation between Prx 1/2 SO3 and Prx 3 SO3 (Figure 26). 
The oxidation status of the Prxs following treatment with H2O2 from 0 to 9 hrs was 
examined next in Neo and HT1 cells. Cell lysates were prepared following treatment 
and subjected to Western blot analysis (Figure 26). Following treatment with H2O2, a 
significant hyperoxidation of Prxs can be observed at 2 hrs in both cell lines as 
compared to the untreated control. Interestingly, with the progression of time, the 
amount of hyperoxidised Prxs diminishes more rapidly in the HT1 cells as compared 
to Neo cells. Since the total amount of Prx remains unchanged over the same time 
course, the data suggest that the hyperoxidised forms are not targeted for degradation 
and most probably regenerated to their active forms. This process of recovery from 
the hyperoxidised state with no change in total expression has also been shown by 
other groups (Chevallet et al., 2003; Woo et al., 2003b). The more rapid decrease in 
the inactive form as has been observed in HT1 cells might mean a larger pool of 






Figure 26: hTERT overexpression increases the rate of peroxiredoxin 
regeneration from the hyperoxidised form. Neo and HT1 cells were treated from 0 
to 9 hrs with H2O2. The cells were then harvested and whole cell lysates were 
prepared. 10 μg or 40 μg of lysates were then subjected to Western blot analysis of 
Prx SO3. The antibody recognizes Prx I/II SO3 which are of the same size and Prx III 










2.1.4 hTERT overexpressing cells maintain a higher intracellular GSH/GSSG 
ratio following H2O2 treatment  
In addition to the above mentioned antioxidant defences, the glutathione antioxidant 
system is a major and critical source of protection from ROS. Indeed, their abundant 
and ubiquitous expression makes them a perfect first line of defence against oxidative 
insults. The GSH/GSSG couple is a reflection of the reduced and oxidized glutathione 
pools present in the cell and a critical indicator of cellular redox status. Thus, it was 
pertinent to investigate if hTERT overexpression may influence this redox couple, 
thus altering the cellular capacity to resist oxidative stress.  
As such, Neo and HT1 cells were exposed to 300 μM H2O2 from 0 to 8 hrs. Following 
treatment, the cells were assayed for their intracellular levels of GSH and GSSG as 
described in the Materials and Methods and the GSH/GSSG ratios were calculated. 
Figure 27 shows that hTERT overexpressing cells maintain a higher GSH/GSSG ratio 




 Figure 27: hTERT overexpressing cells maintain a higher intracellular 
GSH/GSSG ratio following H2O2 treatment. Following treatment with 300 μM 
H2O2, Neo and HT1 cells were prepared as described in the Material and Methods and 
the intracellular (reduced and oxidized) glutathione ratios were computed. All data 











2.1.5 hTERT overexpressing cells maintain higher intracellular mitochondrial   
GSH levels following H2O2 treatment  
Approximately 10% of cellular GSH is found at the mitochondria. Since mitochondria 
do not contain catalase, they depend upon GSH peroxidase and non-enzymatic 
reaction with GSH to protect against ROS and, more specifically, peroxide mediated 
toxicity. With the mitochondria being a key source of ROS, besides studying the total 
intracellular glutathione levels it was also necessary to study the mitochondrial GSH 
levels. Due to the low amounts of glutathione that are present in the mitochondria, this 
assay only allowed for accurate assessment of the reduced form of glutathione in the 
mitochondria. 
Neo and HT1 cells were treated with 300 μM H2O2 for 4 hrs and 8 hrs following 
which the mitochondrial fractions were isolated and the intracellular glutathione 
levels were assayed as described in the Materials and Methods. The rate of reduction 
of GSH levels following H2O2 treatment occurred more rapidly in the Neo cells as 





 Figure 28: hTERT overexpressing cells maintain higher intracellular 
mitochondrial GSH levels following H2O2 treatment. Neo and HT1 cells were 
treated with 300 μM of H2O2 following which they were fractionated to obtain the 
mitochondrial fractions and the intracellular reduced glutathione levels were assayed 
as described in the Material and Methods. All data shown are mean ± SD of at least 
















2.1.6 hTERT overexpression results in earlier and sustained induction of       
glutamate cysteine ligase catalytic subunit levels following H2O2 treatment 
Since the GSH/GSSG ratios were higher in HT1 cells as compared to the Neo cells, 
levels and activity of a few critical enzymes involved in the glutathione regulation 
pathway were assayed next. Glutamate cysteine ligase (GCL) catalyses the first step 
which is also the rate limiting reaction in GSH synthesis. This catalytic subunit of this 
ligase GCLC confers the total enzymatic activity to GCL.  
Thus, its expression was analyzed via Western blot analysis following treatment with 
300 μM H2O2 from 0 to 8 hrs (Figure 29). In HT1 cells, the upregulation of GCLC 
could be detected as early as 2 hrs and remained up to 6 hrs after treatment as 
compared to the Neo cells, where there was a late and transient upregulation of GCLC 
that was detected 6 hours after exposure to H2O2. This could contribute to the 
increased GSH synthesis and the increased GSH/GSSG ratios observed in hTERT 
overexpressing HT1 cells as compared to Neo cells (Figure 27). 
 
Figure 29: Intracellular GCLC levels following treatment with H202. Neo and 
HT1 cells were treated with 300 μM H2O2 following which the intracellular GCLC 





2.1.7 hTERT overexpression results in differential regulation of glutathione 
dependant enzymatic activities  
Glutathione Peroxidase (GPx) and Glutathione Reductase (GR) are important 
regulators of glutathione levels. GPx is a peroxide degrading enzyme that uses GSH 
as a reducing substrate to produce GSSG. GR acts on GSSG and reduces it back to 
GSH. Next, we examined if hTERT overexpression may alter GSH/GSSG ratios by 
modulating the activities of GPx and GR, by assaying intracellular GPx (Figure 30A) 
and GR activity (Figure 31 A) in Neo and HT1 cells. 
 For GPx activity (Figure 30A), the blank is the measure of the background change in 
NADPH absorbance when incubated with cumene hydroperoxide in the absence of 
enzymatic substrate. The rate of change in absorbance is calculated from the linear 
section of the graph. After subtracting the change in absorbance observed for the 
blank, the resultant net change in absorbance (ΔA340/min) was used to calculate the 
activity based on the formula given below. The net GPx activity of Neo and HT1 cells 
obtained from 3 independent experiments performed in duplicates are plotted in 
(Figure 30B). The change in absorbance is greater in HT1 cells as compared to Neo 
cells, indicative of a higher GPx activity in HT1 cells.  
Similarly the GR activity was also assayed. The blank represents the background 
change in NADPH absorbance when no enzymatic substrate is present and the 
ΔA340/min is calculated to compute the activity based on the formula given in the 
Materials and Methods. The calculations for the GR activity are similar to that used 
for the GPx activity as the activities in both assays are computed based on the 
oxidation of NADPH. The net GR activity of Neo and HT1 cells obtained from 3 










Figure 30: Glutathione Peroxidase Activity is increased with hTERT 
overexpression.  Neo and HT1 cells were used to prepare the sample for the GPx 
assay as described in the Materials and Methods. A is representative of the change in 
the NADPH absorbance measured at 340 nm over 15 minutes. In B, the GPx activity 
for both cell lines was calculated from the change in absorbance per minute obtained 
from A, using the formula described in the Materials and Methods. All data shown are 










Figure 31: Glutathione Reductase activity remains unchanged with hTERT 
expression. Neo and HT1 cells were used to prepare the sample for the GR assay as 
described in the Materials and Methods In A, the change in NADPH absorbance was 
measured at 340 nm over 15 minutes. In B, the GR activity for both cell lines was 
calculated from the change in absorbance per minute obtained from A, using the 
formula described in the Materials and Methods. All data shown are mean ± SD of at 





2.2 hTERT overexpression results in improved mitochondrial function 
2.2.1 hTERT localizes to the mitochondria 
The mitochondria is one of the key sources of ROS with mitochondrial O2.-  being the 
primary form in an aerobic cellular system. Given that earlier results have shown a 
significantly lower mitochondrial O2.- in hTERT overexpressing cells, it was of 
interest to investigate if hTERT can help improve mitochondrial function, thus further 
reducing aberrant ROS production. As such, the mitochondrial localization pattern of 
hTERT, which is largely known to reside in the nucleus, was first studied.  
Mitochondrial fractions of Neo and HT1 cells were prepared and the samples were 
then analyzed via Western blot and probed for hTERT. VDAC being a mitochondrial 
marker, was used as a mitochondrial loading control. The results indicated the 
presence of hTERT in the mitochondria with more being present in HT1 cells as 
compared to the Neo cells (Figure 32A). To further elucidate the localization within 
the mitochondria, the mitochondrial fractions were treated with Proteinase K (PK) 
that could digest the outer mitochondrial membrane. The fractions were then analyzed 
by Western blot. Bcl-2 was used a marker for OMM localization. Prohibitin being an 
IMM protein was used as a marker for the IMM localization. VDAC is largely an 
OMM protein but it shows up even after PK treatment since it spans across the OMM 
to the IMM. In contrast Bcl-2 is completely stripped off along with the OMM by 
proteinase treatment. Prohibitin can be observed in equal amounts in the total 
mitochondrial fraction and the IMM fraction suggesting all of the mitochondrial 
prohibitin is localized to the IMM. Unlike prohibitin however, there was a decrease in 
the amount of hTERT in the inner mitochondrial fractions (PK treated fraction) as 




hTERT is probably found in both the IMM and OMM fractions (Figure 32B). A 
recent report by Ahmed et al., 2008 corroborates our findings of hTERT being 
distributed over IMM and OMM. 
 
              
A 
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Figure 32: hTERT localizes to the mitochondria. Neo and HT1 cells were 
fractionated to obtain the cytosolic  and mitochondrial fractions. The mitochondrial 
fractions of HT1 were untreated or treated with 50µg/ml Proteinase K as described in 
the Materials and Methods to remove the outer mitochondria membrane. The fractions 











2.2.2 hTERT expression increases cytochrome c oxidase activity 
The cytochrome c oxidase is the terminal enzyme on the electron transport chain to 
receive and transfer the electrons to oxygen. It has also been viewed upon as the rate 
limiting enzyme of the electron transport chain and hence, its activity has been shown 
to be critical in modulating the efficiency of the mitochondria. The reduction in 
mitochondrial O2.- levels in hTERT overexpressing cells and the localization of 
hTERT to the mitochondria coupled with the functional significance of COX in 
mitochondrial respiration, the role of hTERT in mitochondrial respiration with 
regards to COX was investigated next.  
Mitochondrial fractions were prepared from Neo and HT1 cells following which they 
were analyzed for COX activity as described in the Materials and Methods. HT1 cells 
displayed an increase in COX activity with a more rapid oxidation of ferrocytochrome 
c substrate to ferricytochrome c. The fold difference in the COX activity between Neo 
and HT1 cells obtained from 3 independent experiments are shown in the graph 





 Figure 33: hTERT overexpression increases the COX activity in cells. 30 x 106 
cells were fractionated to obtain the mitochondrial fractions. COX activity was 
measured by monitoring the oxidation of reduced Cyt. C by spectrophotometric 
analysis at 550nm for 2mins at 37C. The data shown are mean ± SD of at least 3 











3. THE EFFECTS OF hTERT EXPRESSION IN AN ALTERNATIVE 
MODEL; SH-SY5Y CELLS  
3.1 Studying the influence of hTERT expression in SH-SY5Y cells 
Studies in the earlier sections have established a model using hTERT overexpression 
in HeLa cells to show the cross talk between hTERT and ROS and also to delineate 
the mechanisms via which hTERT expression can modulate ROS. The SH-SY5Y cell 
line is known to have an elevated hTERT expression. As such, it was chosen to mimic 
the effects of high hTERT expression in a physiologically relevant setting. hTERT 
silencing in the SH-SY5Y cell line served as an alternative model to reiterate the role 
of hTERT in modulating cellular ROS levels.  
 
3.1.1 hTERT silencing in SH-SY5Y cells potentiate the increase in intracellular 
ROS levels following treatment with H2O2  
hTERT silencing was performed in SH-SY5Y cells as described under the Materials 
and Methods with either scrambled si RNA that acted as a negative control (si 
negative control) or with hTERT si RNA (si hTERT). Following 72 hrs of silencing, 
the cells were assayed via Western blot to verify hTERT silencing. Since we 
previously showed that hTERT expression could induce MnSOD expression in the 
cells (Figure 24 A and B), the Mn SOD levels were also assayed following hTERT 
silencing (Figure 34A). Interestingly, Mn SOD expression was downregulated in SH-
SY5Y cells following hTERT silencing. Next, the intracellular levels of ROS were 
assessed using CM-H2DCFDA (Figure 34B). The hTERT silenced cells displayed a 
higher level of intracellular ROS levels compared to the negative control. This 
difference can be observed with greater clarity by reading the percentage of 




Since hTERT overexpression has been shown to improve cellular capacity, thereby 
enabling the cells to resist an increase in intracellular ROS level with ROS inducing 
triggers such as H2O2, it was of interest to investigate if hTERT silencing could then 
reduce the cellular capacity to resist oxidative stress. Thus, hTERT expression was 
transiently silenced in SH-SY5Y cells following which they were treated with 600 
μM H2O2 for 4 hrs. Following the 4 hrs treatment the cells were loaded with DCF-DA 
and analyzed by flow cytometry. The cells silenced with scrambled si RNA (si 
negative) showed little rightward shift following treatment with H2O2. This 
observation was consistent with previous findings in the lab that have shown that 
exposure of SH-SY5Y cells to concentrations of H2O2 ranging between 800 µM -1 
mM could only induce a marginal increase in DCF florescence when stained with 
CM-H2DCFDA and analyzed by flow cytometry. In contrast to these findings, hTERT 
silenced SH-SY5Y cells demonstrated a significant rightward shift following 
treatment with 600 μM of H2O2 (Figure 35) suggesting it is a true physiological 
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Figure 34: hTERT silencing increases basal intracellular ROS levels. hTERT was 
silenced in SH-SY5Y cells over 72 hrs as described in the Materials and Methods. 
Following hTERT silencing, hTERT levels and Mn SOD levels were assayed (A). 
GAPDH was used as a loading control. The basal levels of intracellular reactive 
oxygen species was detected by flow cytometry in the si negative and si hTERT cells 
using the probe CM-H2DCFDA. Histogram (B) and density plot (C) representations 
of the data are shown. The data shown above are a representative of 3 independent 
experiments. 
 
 Figure 35: hTERT silencing accentuates the increase in intracellular ROS levels 
following H2O2 treatment. hTERT silencing was performed in SH-SY5Y cells after 
which the cells were exposed to 600 µM of H2O2 for 4 hrs. Intracellular reactive 
oxygen species was detected by flow cytometry using the probe CM-H2DCFDA. The 



























3.1.2 hTERT silencing reduces the rate of peroxiredoxin regeneration from the 
hyperoxidised form in SH-SY5Y cells 
Having observed a reduced capacity to tolerate oxidative stress in hTERT silenced 
SH-SY5Y cells, and since hTERT expression has been shown to accelerate the 
regeneration of hyperoxidised Prx, the Prx oxidation status was examined next in 
hTERT silenced SH-SY5Y cells. Transient hTERT silenced SH-SY5Y cells were 
treated with 600 μM H2O2. The lysates were then analyzed by Western blot analysis 
to assess the hyperoxidised Prx SO3 forms. (Figure 36). Following 8 hrs of treatment, 
there was a greater reduction in the hyperoxidised form of Prx SO3 in si negative SH-
SY5Y cells as compared with the hTERT silenced SH-SYFY cells. Though in both si 
negative and si hTERT silenced cells the regeneration of Prx III SO3 seems to be 
generally slower then that of Prx I / II SO3; in si RNA negative treated cells the 
regeneration of Prx I / II SO3 is faster then that observed in si hTERT silenced cells 
following H2O2 treatment.  
3.1.3 hTERT silencing results in decreased GSH/GSSG ratios following H2O2 
treatment in SH-SY5Y cells 
Since cells overexpressing hTERT have been shown to maintain a higher GSH/GSSG 
ratio in the face of oxidative stress, it was examined next if hTERT silencing could 
reverse this effect on GSH/GSSG ratio. Thus, following hTERT silencing, the SH-
SY5Y cells were treated with 600 μM H2O2 for 4 hrs and 8 hrs. The intracellular 
glutathione levels were then assayed as previously described. hTERT silenced SH-
SY5Y cells displayed reduced GSH/GSSG ratios compared to the negative control, 




findings substantiate the reversed observations made with hTERT overexpression 
(Figure 37). 
 
Figure 36: hTERT silencing reduces the rate of Peroxiredoxin regeneration from 
the hyperoxidised form following H2O2 treatment. hTERT silencing was performed 
in SH-SY5Y cells after which the cells were exposed to 600 µM of H2O2 from 0 to 8 
hrs. The cells were then harvested and whole cell lysates were subjected to Western 
blot analysis of Prx SO3. The antibody recognizes Prx I/II SO3 which are of the same 
size and Prx III SO3. Beta actin was used as a loading control. 
 
 
Figure 37: hTERT silencing reduces intracellular GSH/GSSG ratio following 
H2O2 treatment. hTERT silencing was performed in SH-SY5Y cells after which the 
cells were exposed to 600 µM of H2O2 from 0 to 8hrs. Following treatment, the cells 
were prepared as described in the Material and Methods and the intracellular (reduced 
and oxidized) glutathione ratios were computed (A). Data shown are mean ± SD of 





With the establishment of the effects of HTERT expression on cellular redox status 
and the possible mechanisms via which hTERT expression may elicit these effects, it 
was of interest to study next the physiological relevance of these findings with regards 
to cell fate. More specifically, given the antagonistic effect of hTERT on ROS, it was 
of greater interest to study the ROS mediated engagement of cell death which is the 
mitochondrial death pathway. 
4. hTERT EXPRESSION IMPAIRS ROS INDUCED CHANGES IN 
INTECELLULAR MILIEU AND PROTECTS FROM CELL DEATH  
4.1 Induction of cytosolic acidification by H2O2 and C1 is reduced in hTERT 
overexpressing cells. 
We have previously demonstrated in the lab that H2O2, added exogenously or 
triggered endogenously using C1, is a stimulus for cytosolic acidification which 
creates a permissive intracellular milieu for death execution. Pre-treatment with 
scavengers such as catalase has also been shown to block the induction of cytosolic 
acidification hence arresting the downstream apoptotic cascade (Ahmad et al., 2004; 
Hirpara et al., 2001). Since hTERT expression lowers intracellular ROS and arms the 
cells with the ability to resist oxidative stress, it was next tested if hTERT expression 
could antagonize the cytosolic acidification that ensue H2O2 or C1 treatment. 
To that end, Neo and HT1 cells were treated with 300 μM H2O2 or 100 μg/ml of C1 
for 6 hrs and 4 hrs respectively. Following treatment, the cells were loaded with 29, 
79-Bis (2-carboxyethyl)-5, 6- carboxyfluorescein (BCECF) and intracellular pH was 
assessed. Both H2O2 (Figure 40A and 40B) and C1 (Figure 41A and 41B) triggered 




intracellular pH was less in HT1 cells as compared to the Neo cells. Following H2O2 
treatment, the change in intracellular pH of the Neo cells (Figure 40A) and HT1 cells 
(Figure 40B) was - 0.807 and -0.196 respectively as compared to their respective 
control cells. Similarly, treatment with the drug C1 also exhibited a reduced 
acidification in HT1 cells (Figure 41 B) with a drop of -0.272 as opposed to -0.432 
that was observed in the Neo cells (Figure 41A). The average changes in the 
intracellular pH following treatment with Neo and HT1 cells following treatment with 
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Figure 38: H2O2 induced cytosolic acidification is reduced in hTERT 
overexpressing cells. In A and B, Neo cells (A) and HT1 cells (B) were treated with 
300 µM H2O2 for 4 hours. Following treatment, they cells were loaded with BCECF 
and intracellular pH was assessed by flow cytometry. Changes in intracellular pH 
(pHi) after addition of H2O2 is tabulated and shown in C. All data shown are mean ± 
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Figure 39: C1 induced cytosolic acidification is reduced in hTERT 
overexpressing cells. In A and B, Neo cells (A) and HT1 cells (B) were treated with 
100 μg/ml C1 for 4 hours.  Following treatment, they cells were loaded with BCECF 
and intracellular pH was assessed by flow cytometry. Changes in intracellular pH 
(pHi) after addition of C1 is tabulated and shown in C. All data shown are mean ± SD 








4.2 Mitochondrial Bax translocation and release of pro-apoptogenic factors is 
partially inhibited in hTERT overexpressing cells 
Cytosolic acidification can signal the translocation of Bax to the mitochondria. At the 
mitochondria, formation of pores in the mitochondria by Bax can lead to the collapse 
of the electrochemical gradient across the mitochondrial membrane and the drop in 
mitochondria membrane potential. The subsequent release of pro-apoptogenic factors 
such as Cyt. C and SMAC into the cytosol can lead to the activation of the 
downstream death execution pathway.  
Neo and HT1 cells were treated with 300µM H2O2 or 100 μg/ml of C1 for 12 hrs. 
Following treatment, cytosolic and mitochondrial enriched fractions of Neo and HT1 
cells were prepared and analyzed via Western blot for the above mentioned apoptotic 
proteins (Figure 42). Results show that there is reduced translocation of Bax to the 
mitochondria following treatment with H2O2 or C1 in HT1 cells as compared to Neo 
cells. In addition, lesser expression of pro-apoptogenic factors such as Cyt. C and 







Figure 40: hTERT overexpression partially inhibits Bax translocation and Cyt. 
C and SMAC release. Neo and HT1 cells were treated with 300µM H2O2 or 100 
μg/ml C1 for 12 hours. The cells were then harvested and fractionated to obtain the 
cytosolic and mitochondrial fractions. The samples were subjected to Western blot 
analysis of Bax, Cyt. C and SMAC. Beta actin was used as a cytosolic loading control 










4.3 Dissipation of the mitochondrial membrane potential (m) is reduced in 
hTERT overexpressing cells 
Mitochondrial permeability transition (MPT) is an important step in the induction of 
cellular apoptosis. Since the electrochemical gradient is essential for ATP synthesis, 
dissipation of the m can commit the cell to death. Since the release of pro-
apoptogenic proteins from the mitochondria strongly suggests mitochondrial 
membrane permeabilization, the m was assessed next.  
Neo and HT1 cells were treated with 300 µM H2O2 or 100 μg/ml of C1 for 6 hrs. The 
cells were then stained with DIOC6 and analyzed by flow cytometry. The drop in 
m following treatment with H2O2 (Figure 43A) or C1 (Figure 44) was greater in 
Neo cells as opposed to HT1 cells. This difference in the drop in m can be read by 
comparing the extent of leftward shift in the cell populations stained with DIOC6. 
This partial rescue from the drop in membrane potential with hTERT overexpression 
suggested that HT1 cells may be able to survive the ROS mediated death triggers 
better. 
To further substantiate these findings, the alterations in the m of ROS triggered- 
hTERT silenced SH-SY5Y were also analyzed. The SH-SY5Y cells were silenced 
with either scrambled si RNA that acted as a negative control (si negative control) or 
with hTERT si RNA (si hTERT). Following 72 hrs of silencing, the cells were 
assayed for their m   using DIOC6. As with hTERT overexpression, hTERT 
silencing also did not show a difference in their basal m when compared with the 




displayed a greater drop in membrane potential as compared to the control cells 
(Figure 43B). 











Figure 41: hTERT overexpression reduces the drop in membrane potential 
following treatment with H2O2. Neo and HT1 cells were treated with 300 μM of 
H2O2 for 6 hrs after which the cells were harvested and the mitochondrial membrane 
potential was detected by flow cytometry using the probe DIOC6 (A). The data shown 
in A is a representative of 4 independent experiments. hTERT was silenced in SH-
SY5Y cells over 72 hrs as described in the Materials and Methods following which 
the cells were treated with 600 μM of H2O2 for 6 hrs. Thereafter, the mitochondrial 
membrane potential was assessed using DIOC6 (B). The data shown in B above are a 









Figure 42: hTERT overexpression reduces the drop in membrane potential 
following treatment with C1. Neo and HT1 cells were treated with 100 µg/ml of C1 
for 3 hrs after which the cells were harvested and the mitochondrial membrane 
potential was detected by flow cytometry using the probe DIOC6 as described in the 
Materials and Methods. Win MDI software was used to analyse the data and present it 











4.4 hTERT overexpression can protect cells from H2O2 mediated cell death 
Given hTERT expression was found to confer resistance to both changes in 
intracellular ROS levels and the engagement of mitochondrial death pathways 
following exposure to ROS triggers, it was hypothesized that this could be a 
mechanism to make hTERT overexpressing cells more robust against ROS induced 
cell death triggers. Thus, the short term and long term effects of the ROS mediated 
apoptosis inducing triggers were tested on control and hTERT overexpressing cells.  
As used previously, the cells were firstly treated with H2O2 in a dose dependant 
manner from 0 to 300 µM over 18 hrs and then cell viability was assessed using 
crystal violet staining. HeLa ATCC cells and Neo cells were significantly more 
susceptible to H2O2 treatment as compared to hTERT overexpressing HT1 and HT2 
cells (Figure 45). A significant protection against H2O2 could be observed at the 
higher doses of 200 µM and 300 µM in both HT1 and HT2 cells. 
To further characterize the loss of cell viability, DNA fragmentation as a hallmark of 
apoptosis was assessed next. Propidium Iodide (PI) is the most commonly used dye to 
quantitatively assess DNA content as it binds to DNA by intercalating between the 
bases with little or no sequence preference. As such, PI staining can be used to 
identify the apoptotic population of cells containing fragmented DNA via flow 
cytometry analysis. Neo and HT1 cells were exposed to the higher doses of 150 µM 
and 300 µM of H2O2 over 18 hrs. Following treatment, the cells were permeabilized 
and stained with PI to assess the apoptotic populations represented by the sub-G1 
population (Figure 46 A). The percentage of sub G1 population was lesser in HT1 
(6.2% and 12.9%) cells as compared with Neo cells (16.27% and 21.84%) at 150 µM 




In cancer therapeutics, the ability to induce cell death is insufficient for a successful 
chemotherapeutic regiment. Tumor cells metabolize the drugs over time and can 
acquire the ability to overcome the potentially lethal effects of the drugs, thus 
surviving the cytotoxic hit. Thus, it is important to assess the regenerative capacity of 
the cells following a cytotoxic hit which, in a tumour context, translates to the ability 
of a single tumour cell to divide and form colonies following a drug trigger. In this 
study, in order to investigate if hTERT expression might be able to influence the 
colony forming capacity of these tumor cells following treatment with H2O2, HeLa 
Neo and HT1 cells were treated with 300 µM of H2O2 for 18 hrs. Following treatment, 
the cells were replated onto 100 mm culture plates and incubated for 10 to 14 days. In 
the Neo plates, following treatment, there was an almost total wipe-out of colonies. In 
contrast, HT1 cells showed a significantly improved ability to form colonies 







 Figure 43: hTERT overexpression can protect from H202 mediated apoptosis. 
HeLa ATCC, Neo, HT1 and HT2 cells were treated with H2O2 in a dose dependant 
manner for 18hr from 0 to 300µM (A). The crystal violet assay was then done on 
these cells as described in Materials and Methods to determine cell viability after 18 










Figure 44: Cell cycle analysis to show that hTERT overexpression can protect 
from H202 mediated apoptosis. Neo and HT1 cells were treated with 150µM and 
300µM of H2O2 and stained with propidium iodide for DNA fragmentation analysis 
by flow cytometry. The cell cycle profiles shown are representative of three 






Figure 45: hTERT overexpression promotes the colony-forming ability of cells 
which have been treated with H2O2. HeLa cells were exposed to 300µM H2O2 for 
18 hours. The cells (5000 – 10000 cells) were then seeded in 100 mm Petri dishes and 
allowed to form colonies over 8 to 14 days, after which they were stained with crystal 
violet as described in Materials and Methods to show colony formation. 














4.5 hTERT overexpression can protect cells from C1 induced cell death 
Since hTERT overexpression could protect cells from H2O2 induced cell death, it was 
next examined if hTERT expression could also confer resistance against drugs which 
could induce intracellular ROS. Thus, Neo and HT1 cells were treated with 50 µg/ml 
or 100 µg/ml of C1 for 18 hrs. Following treatment the cell viability was assessed 
with crystal violet staining (Figure 48). hTERT overexpressing cells were more 
resistant to C1 induced cell death as compared with Neo cells, with approximately a 
20% rescue from cell death with hTERT overexpression.  
In line with the improved colony forming ability observed with H2O2 treatment in 
hTERT overexpressing cells, the colony forming ability of these cells treated with  
100 µg/ml C1 for 12 hrs were assessed next (Figure 49A). Similar to the results 
obtained after treatment with H2O2, HT1 cells displayed an improved colony forming 
ability as compared with Neo cells. Indeed, there was a 20% increase in colony 






 Figure 46: hTERT overexpression can protect from C1 mediated apoptosis. Neo 
and HT1 cells were treated with 50 µg/ml or 100 µg/ml C1 for 18hr (A). The crystal 
violet assay was then performed on these cells to determine cell viability after 18 
hours. All data shown are mean ± SD of at least three independent experiments. 
 
 









Figure 47: hTERT overexpression promotes the colony-forming ability of cells 
which have been treated with C1. HeLa cells were exposed to 100 µg/ml of C1 for 8 
hours. The cells (5000 - 10000) were then seeded in 100 mm petri dishes and allowed 
to form colonies over 8 to 14 days, after which they were stained with crystal violet. 

















1. THE USE OF DIFFERENT MODELS IN THIS STUDY 
In this thesis, the different models that have been used with respect to cell lines and 
ROS triggers have served as important cross references to corroborate and strengthen 
some of the key findings such as the impact of hTERT expression on cellular redox 
status and the key antioxidant defences. These findings help to illustrate that the 
effects observed are not due to a random, isolated or independent event that occurred 
with hTERT expression.  
1.1 The HeLa cell line and the limitations in telomerase biology 
At the outset of this study, the HeLa cell line was chosen as it has been reported to be 
a good working model for hTERT related studies due to the detectable levels of 
hTERT expression and activity (Huang et al., 2002; Kurvinen et al., 2006; Satra et al., 
2006). Unfortunately, the lack of good antibodies available against hTERT largely 
limited our scope of study in the initial phase despite having a good cell line to work 
with. Many of the antibodies that are commercially available against hTERT are not 
sensitive enough to pick up the correct band as they often picked up bands that did not 
correspond to the expected size of 127kDa. Indeed for a long time, a band size around 
100kDa was thought to be consistent with the estimated molecular weight of 127 kda 
for hTERT by many groups. These inconsistencies were eventually resolved by a 
detailed study conducted by Wu et al where it was shown that the hTERT antibody 
(Novocastra, NCL-hTERT, clone 44F12) that was being commonly used by numerous 
groups (Brustmann, 2005; Dalerba et al., 2005; Dutu et al., 2005; Kraemer et al., 




et al., 2006). Thus the lack of a specific antibody was one of the major limiting 
factors in the telomerase field in the earlier phases of this study. As such, we had to 
seek alternatives such as HA-tagged or Flag-tagged hTERT plasmids to transfect and 
detect hTERT expression using HA antibody or Flag antibody and RT-PCR to 
analyze hTERT levels. However, given that RNA levels are not always a true 
reflection of protein levels, the search for alternative antibodies carried on. The break 
eventually came following the assessment of several antibodies in the market which 
ran us into the hTERT antibody from Epitomics. This rabbit monoclonal antibody was 
a highly specific antibody and it picked up the band corresponding to 127kDa. 
Despite being a highly specific antibody, it is a relatively weak antibody requiring 
very low dilutions of primary and secondary solutions for Western blotting.  
In this regard, the use of HeLa cells was certainly ideal due to the moderate 
abundance of hTERT, thus facilitating the process of Western Blot analysis further. In 
order to assess the effects of hTERT on the cell, a model overexpressing hTERT was 
required. Due to the necessity to compare the effects between hTERT overexpression 
with the control vector transfected controls, it was decided that the transfections 
would be performed in HeLa cells as this would allow us also to assess the controls 
well too. In addition, HeLa cells are also known to be more amenable to transfection 
processes, thus making them a natural candidate. 
1.2 The use of transient and stable transfection models in this study 
Transient transfection is a good model to assess the immediate effects of any gene that 
is introduced into the system. However, this protocol can also be limited by the 
efficiency of transfection and the fluctuating time frame over which the protein is 




assessment of cellular changes that occurs immediately with an imbalance in cellular 
hTERT levels, it was not feasible to assess all the parameters by transient transfection 
models alone as the transfections only lasted between 48hrs to 96hrs and many of the 
studies required large numbers of cells. Thus, stable clones of hTERT were also 
generated (Figure 19).  
Heterogeneous populations were chosen over homogenous populations to rule out the 
effects observed in the cells due to alterations in a single cell following hTERT 
expression. Several heterogeneous populations were generated of which only HT1 
and HT2 cells eventually survived the selection process. After assessing the initial 
parameters to ensure that both HT1 and HT2 showed similar traits, especially with 
regards to intracellular ROS levels, all subsequent experiments were conducted in 
HT1 cells as a representative of a stable hTERT overexpressing model in HeLa cells. 
Cross referencing between the transient transfection model and the stable clones also 
provided a good measure of reproducibility on the effects observed with hTERT 
expression, especially with regards to cellular ROS levels. Since it is a common fear 
that stable cell lines may undergo further cellular changes with time, the stable clones 
were not used beyond 15 – 20 passages.  
The neuroblastoma cell line SH-SY5Y was selected as it been reported to have a 
relatively high expression of hTERT as observed with most other aggressive 
neuroblastomas (Binz et al., 2005). Therefore this cell line provided an elevated and 
yet physiological model to work with. Given that there were also some initial findings 
about this cell line in our lab with respect to its ability to resist oxidative stress, the 





1.3 The use of H2O2 and C1 as tools to investigate the relationship between 
hTERT and ROS and the different time points at which the investigations were 
performed. 
The findings in this study have been largely based on the cellular responses to H2O2 
and C1. H2O2 was an excellent tool to assess the cellular outcome of direct exposure 
to ROS. Though many drugs can induce cellular ROS, usually ROS production is 
accompanied by numerous secondary events that elicit other deleterious effects on the 
cells.  In this regard, using a direct ROS stimulus such as H2O2, the unwanted 
secondary cellular responses could be diminished and the net effects observed could 
be attributed in large to the effects of ROS itself. Throughout the study an apoptosis 
inducing dose of 300 µM was used on both Neo and HT1 cells in order to stimulate an 
environment that could induce considerable oxidative stress and apoptosis and yet 
could elicit the protective response from hTERT. The use of very high concentrations 
(> 500 µM) of ROS was avoided as, based on findings in the lab, these doses elicited 
necrotic effects on HeLa cells. However, in contrast to HeLa cells, the SH-SY5Y cells 
have been shown to be relatively more resistant to higher concentrations of H2O2 and 
it has been reported that concentrations of 500 µM – 600 µM have been used to assess 
ROS induced apoptosis (Tetich et al., 2004; Wang et al., 2009). Thus, the dose of 600 
μM was used with SH-SY5Y cells. 
In addition to using exogenous ROS, it was also of interest to investigate the effects of 
hTERT expression with endogenous ROS induction. C1 is an experimental drug that 
has been synthesized in our lab and has been used as a tool to study the effects of drug 
induced ROS in cells (Figure 17A). Like other drugs, though C1 can elicit secondary 




over other agents for two reasons. Firstly, it could induce a significant production of 
endogenous ROS and secondly, the cellular outcomes of treatment with C1 have been 
well mapped out from previous studies in the lab (Ahmad et al., 2004; Hirpara et al., 
2001; Pervaiz et al., 1999b). As such, it provided a good basis for comparison 
between the probable outcomes and the deviations observed. 
The time points used in this thesis to measure celllar ROS levels, antioxidant 
defenses, and engagement of the mitochondrial events and eventually cell death were 
staggered in a progressive manner. Induction of cellular ROS is known to be an early 
event which we observed within the first few hours. Similarly, the induction of 
antioxidant defences were also assayed two hourly over the first 8 hours. This allowed 
us to understand better, how the cells responded after exposure to ROS triggers, over 
the time course investigated as cell death engagement events, following ROS triggers 
can be muted by antioxidant defences. In addition, no significant cell death was 
observed in the first 12 hrs following treatment. Since the levels of cell death were 
more pronounced by 18 hrs, it was logical to expect the engagement of mitochondrial 
events to occur at an earlier time points.  In our studies based on kinetic studies 
engagement of mitochondrial events were observed between 6 hrs and 12 hrs. 
2 ESTABLISHING THE RELATIONSHIP BETWEEN hTERT AND ROS 
2.1 ROS mediated suppression and nuclear export of hTERT can be 
antagonized by hTERT overexpression 
hTERT expression is controlled by numerous redox sensitive transcription factors, 
hence it comes as no surprise that exposure to ROS can regulate hTERT expression. 




had to re-establish the effects of ROS on hTERT expression in our model. This 
incited the investigation on studying hTERT expression, localization and activity 
following ROS exposure. Treatment to high levels of ROS has been previously shown 
to lead to the oxidation of one of its transcription factors SP1 which then results in 
reduced binding of SP1 to hTERT and c-myc promoter, thus reducing hTERT 
expression (Chou et al., 2005; Chou et al., 2001). Given that c-myc is also a 
transcriptional activator of hTERT, this can further the decrease of hTERT 
expression. Corroborating these findings in our study, exposure of HeLa cells to 
increasing doses of H2O2 had a suppressive effect on hTERT expression (Figure 12). 
Furthermore, at high concentrations of H2O2 (300 μM), nuclear export of hTERT was 
observed with increasing levels observed in the cytosol (Figure 13). Following the 
inception of the stable cell lines, these results were verified. We postulated that 
exposure of the Neo and HT1 cells to H2O2, will lead to a comparable decrease in 
hTERT expression in both cell lines replicating the earlier outcomes observed with 
untransfected HeLa cells. Intriguingly, the extent of downregulation of hTERT 
expression was clearly lesser in HT1 cells as compared to Neo cells (Figure 23A).  
hTERT is required at the nucleus for the functional assembly of telomerase, DNA 
repair and the maintenance of telomeric ends. Haendeler et al has reported that under 
conditions of oxidative stress TERT is tyrosine phosphorylated and exported out of 
the nucleus (Haendeler et al., 2003). Treatment with antioxidants such as N-
Acetylcysteine has been shown to inhibit nuclear export of hTERT (Haendeler et al., 
2004). To that end, studies have shown that oxidative stress induced nuclear export of 
hTERT and can lead to enhanced apoptosis sensitivity and accelerated senescence in 




been reported to confer resistance against apoptotic triggers independent of their 
telomerase activity (Haendeler et al., 2003; Haendeler et al., 2004; Jakob et al., 2008).  
It was initially expected that with a higher hTERT expression, given that all other 
conditions are the same, an increased nuclear export should be observed with HT1 as 
there are more units of hTERT in the nucleus. Contrary to our postulation, HT1 cells 
displayed a decreased nuclear export with H2O2 as compared to Neo cells (Figure 
23B). This observation raised the question on how hTERT was able to antagonize the 
ROS mediated effects on nuclear export and hTERT downregulation. With transient 
hTERT overexpression having shown reduced cellular levels of ROS, one postulation 
was the ability of hTERT to enhance the cellular capacity to resist oxidative stress, 
thus leading to nuclear retention of hTERT in HT1 cells and conferring survival 
advantages onto HT1 cells.  
2.2 hTERT expression significantly reduces basal intracellular ROS levels 
and antagonizes the increase in cellular ROS levels in response to oxidative 
stress. 
In order to nail down the influence of ROS on hTERT, the effects of hTERT 
expression on cellular redox balance were studied in several models. hTERT 
expression in HeLa cells in both transient and stable models displayed a significant 
reduction in basal intracellular ROS levels when analyzed with CM-H2DCFDA 
(Figures 14 and 20A) Mitosox Red (Figures 15 and 20C). To further test the ability of 
hTERT in conferring resistance against oxidative insults, control and hTERT 
expressing cells were treated with exogenous ROS, H2O2 (Figures 16 and 21) and 
endogenous ROS inducing trigger, C1 (Figures 17 and 22). Following treatment with 




control and hTERT overexpressing cells, hTERT overexpressing cells clearly 
demonstrated a reduced induction of cellular ROS levels as compared to the control 
cells. These data, though in contrast to that presented by Santos et al who showed that 
hTERT expression can exacerbate cellular ROS levels, are in agreement with two 
recent reports which have suggested that hTERT expression in MRC 5 cells can 
reduce their cellular ROS levels (Ahmed et al., 2008; Haendeler et al., 2009; Santos et 
al., 2004). Moreover, the significant increase in cellular ROS levels that were 
observed with hTERT silencing and H2O2 treatment in SH-SY5Y cells, as compared 
to the control si negative treated cells (Figures 34 and 35), further substantiated these 
findings. Cumulatively our studies provide conclusive and direct evidence to show, 
for a first time in a variety of models, that hTERT expression can antagonize the 
cellular redox balance and reduce the induction of intracellular ROS in response to 
both exogenous and endogenous oxidative triggers.  
3. MECHANISMS THAT hTERT CAN EMPLOY TO MODULATE 
CELLULAR ROS LEVELS 
As cancer cells advance through the various stages of the disease, due to the persistent 
oxidative stress that they are subjected to, they can become highly adapted to the 
stress. Indeed, under such adverse conditions, these cancer cells can mobilize adaptive 
mechanisms which can activate ROS-scavenging systems or modulate the efficiency 
of cellular processes to limit aberrant production of ROS by-products. Together, these 
redox adaptive mechanisms keep the ROS levels within the range that allow cancer 
cells to escape severe oxidative damage and survive under stress and ROS-mediated 




3.1 Cellular Antioxidant Defences 
Given the improved ability to contain ROS levels under oxidative insult, the cellular 
antioxidant defence system was a natural candidate to be tested to see if hTERT 
expression could modulate the antioxidant defences and offer survival advantages. 
The antioxidant defence network is a wide and intricate network. However, within 
this network there are a few major regulatory circuits which are critical for redox 
homeostasis. These defences were carefully selected based on the type of ROS they 
mainly act upon, their cellular localization and accessibility to the ROS the cells are 
exposed to.  
Since hTERT expression could effectively antagonize the surge in cellular ROS levels 
following exposure to H2O2 and C1 induced H2O2 (Hirpara et al., 2001; Pervaiz et al., 
1999b), attention was firstly turned on to antioxidants that could target cellular 
peroxides. Based on numerous studies and reviews on antioxidant defences 
(Halliwell, 1999; Hofmann et al., 2002; Imlay, 2008; Rhee et al., 1999; Schafer and 
Buettner, 2001; Storey, 1996; Wood et al., 2003a), catalase, peroxiredoxins and the 
glutathione antioxidant system, which are known to form the critical first line of 
defence against cellular peroxides, were chosen. In addition to their ability to mop up 
peroxides, the localization of these antioxidants, as mentioned earlier in the 
introduction, complemented each other offering cell wide antioxidant coverage. 
Mitochondria are one of the key sources of cellular ROS due to their fundamental role 
in respiration. The primary species that is produced at the mitochondria is O2.- which 
can then undergo dismutation to yield H2O2. Thus, the mitochondrial antioxidant 
defences were assessed next. Based on reports and our findings which showed 




mitochondrial GSH and mitochondria localized peroxiredoxins were chosen for 
assessment. 
3.2 hTERT expression can enhance the Glutathione antioxidant defences 
GSH, via its sulfhydryl group, has been shown to play a critical role in cellular 
defence against numerous injurious events. In this regard, in many cell types, the 
GSH-GSSG oxidation-reduction cycle has been shown to be pertinent in conserving 
the structural and functional viability of the cells by providing a mechanistic control 
or signal for functional changes in the cell (Schafer and Buettner, 2001). In addition, 
agents that alter the cellular GSH concentrations have been shown to alter the 
transcription of other detoxification enzymes, cell proliferation and cell death 
mechanisms. Therefore, the GSH/GSSG redox state can be viewed upon as the mirror 
of cellular redox status (Jones, 2002). This is why alterations in the cellular 
GSH/GSSG ratio can have immense significance on cell survival (Meister and 
Anderson, 1983; Storey, 1996).  
In this study it was illustrated that when Neo and HT1 cells were treated with 300 μM 
of H2O2, the Neo cells displayed a more rapid decline in the GSH/GSSG ratio as 
opposed to the HT1 cells (Figure 27). Similarly, in SH-SY5Y cells, a greater decline 
in the GSH/GSSG ratio was observed in the H2O2 treated hTERT silenced cells as 
compared to the si negative cells (Figure 37), further corroborating the results 
obtained with Neo – HT1. A decrease in the GSH/GSSG ratio is usually due to an 
increased oxidation of GSH to GSSG and a lack of replenishment of the GSH to 
compensate for the oxidation. In addition, given that the cytosolic ratios between GSH 
and GSSG ranges from 10:1 up to 100:1, the differences in the ratio is largely 




hTERT on the glutathione system, some of the key enzymes regulating the cellular 
GSH and GSSG levels were assayed next.  
Assessment of GPx activity, which oxidizes GSH to GSSG whilst reducing cellular 
peroxides, demonstrated a 20% increase in basal GPx activity in HT1 cells as 
compared to Neo cells (Figure 30). However, assessment of GR activity, which is 
essential for the conversion of GSSG back to GSH, showed no comparable 
differences between Neo and HT1 cells (Figure 31). The elevated GPx activity and a 
lack of difference in GR activity in HT1 cells raised the question on how GSH levels 
might have been regulated to maintain an elevated GSH/GSSG ratio in the HT1 cells.  
Both GSH loss and GSH oxidation have been associated with an increased expression 
of the rate-limiting enzyme of GSH synthesis, glutamate cysteine ligase (GCL), and 
several other detoxification systems.  Thus, this prompted further analysis on the 
catalytic subunit of glutamate cysteine ligase (GCLC) which catalyses the rate 
limiting step of GSH synthesis (Halliwell, 1999; Meister, 1988a, b; Meister and 
Anderson, 1983).  
The results demonstrated an early and sustained induction of GCLC in response to 
H2O2 exposure in HT1 cells. This was in clear contrast to the transient and late 
activation of GCLC observed in Neo cells (Figure 29). Since GCLC is key to GSH 
synthesis, an early and sustained induction of GCLC following oxidative stress in 
hTERT expressing cells would certainly help to antagonize a rapid decline in cellular 
GSH levels, thus contributing to their higher GSH/GSSG ratios. In addition, the 
increased basal GPx activity could contribute to the lowered basal cellular ROS levels 




3.3 hTERT expression improves peroxiredoxin regeneration 
The assessment of Prx I, II and III reflected no significant changes in their levels with 
H2O2 treatment. Prx I and II are found in abundance in the cytosol making them one 
of the prime regulators of H2O2 signalling. Prx III is localized to the mitochondria 
(Rhee et al., 2005a). In response to ROS stimuli such as H2O2, Prx undergo oxidation 
to mop up cellular peroxides and to protect other cellular proteins from oxidative 
damage. Trx are important in the regeneration of the Prx that have been oxidized to 
the sulfenic forms. However, hyperoxidation of Prx can lead to the inactivation of Prx 
and their regeneration would require repair proteins such as sulfiredoxins and/or 
sestrins. In this regard, several studies have shown this regeneration process by 
monitoring the total and hyperoxidised forms of Prxs and used these varied forms of 
Prx to assess cellular Prx activity (Woo et al., 2003b; Jonsson and Lowther, 2007).  
The detection of sulfonylated proteins has largely relied on complex proteomics 
analysis. The method undertook in this thesis is an alternative to the complex 
procedure involving isotopic labelling of the cells, two dimensional electrophoresis 
and mass spectrometry for the detection of proteins containing hyperoxidised cysteine 
residues. Indeed, the comparison of the older protocols to the use of these antibodies, 
that were produced in response to a sulfonylated peptide modelled on the active site 
sequence common to mammalian Prx I to IV, has illustrated that this antibody is 
equally effective and this protocol is comparable to the older protocols (Woo et al., 
2003b). 
 
The assessment of Prx activity via the study of the hyperoxidised forms of Prx I, II 




cells as compared to Neo cells (Figure 26). Since the total amount of Prx remains 
unchanged over the same time course (Figure 25), the data suggest that the 
hyperoxidised forms are not targeted for degradation and most probably regenerated 
to their active forms. However, when comparing Prx I and II to Prx III, it was 
observed that the decline in the hyperoxidised form of Prx I and II was generally 
faster than that observed with Prx III in Neo, HT1 and hTERT silenced SH-SY5Y 
cells. Studies have attributed this slower rate of regeneration of the hyperoxidised Prx 
III to its active form, to the reduced accessibility of the repair proteins to the 
mitochondria localized Prx III (Budanov et al., 2004; Chevallet et al., 2003).  
Cumulatively, the more rapid decrease in the inactive form as has been observed in 
hTERT overexpressing cells might also mean a larger pool of active Prx available to 
target cellular peroxides in the cells.  
3.4 hTERT expression enhances mitochondrial antioxidant defences 
An upregulation in the Mn SOD levels was noted in the HT1 and HT2 cells as 
compared to the Neo or untransfected ATCC cells (Figure 25A). These findings were 
substantiated further by the increase in Mn SOD expression that was observed with 
transient hTERT expression (Figure 25B) and the decrease in Mn SOD levels that 
were observed in SH-SY5Y cells following hTERT silencing (Figure 25C). Mn SOD 
expression has been long associated with its ability to elicit a tumour suppressive role 
via the induction of growth arrest and inhibition of cell proliferation. But these effects 
were also largely attributed to the enzymatic conversion of O2.- to H2O2 thus leading 
to H2O2 mediated tumour suppressive effects and numerous reports have also shown 




Hence, the upregulation of hTERT, which is a protein that is keenly associated with 
malignancy, leading to an increase in Mn SOD expression is indeed a curious and 
unexpected finding. At this junction, it has to be reiterated that despite the strong 
correlation of hTERT expression with cancer, hTERT merely confers the power of 
immortalization which cannot be equated to transformation and hence, the 
upregulation of Mn SOD levels with hTERT expression cannot be dismissed on the 
basis of the tumour suppressive role of Mn SOD or the reduced levels of Mn SOD 
that is usually found in cancer cells. Here, the upregulation of Mn SOD in hTERT 
overexpressing cells might play a significant role in reducing oxidative stress at the 
mitochondria and contribute to the reduced levels of mitochondrial superoxide that 
have been observed with hTERT overexpression in this study (Figures 15 and 20). 
In addition, the assessment of mitochondrial GSH showed an increase in 
mitochondrial GSH in HT1 cells as compared to Neo cells within 4 hrs of H2O2 
treatment (Figure 28). Due to the inability of the assay to detect very low amounts of 
GSSG from the mitochondrial samples, the GSSG levels could not be measured and 
the GSH/GSSG ratio could not be calculated. Nevertheless the data showed a more 
rapid depletion of mitochondrial GSH in the Neo cells as compared to the HT1 cells. 
Since mitochondrial GSH is usually used as a secondary line of defence as cells 
normally rely on the primary cytosolic pool of GSH to vanquish cellular peroxides, 
the slower mitochondrial depletion of GSH in HT1 cells is a reflection of the hTERT 
overexpressing cells’ enhanced ability to manage oxidative stress.  
3.5 How hTERT could modulate the antioxidant defences? 
If this study could be broken up into milestones, then grounding the link between 




which, the identification of downstream targets that could be differentially regulated 
with hTERT expression, thus leading to the lowered cellular ROS levels would entail 
the next milestone. At this junction, having identified specific antioxidants as 
downstream targets of hTERT expression, the logical question would be how exactly 
hTERT might be altering the levels and activity of these antioxidant defences? 
Though this question could not be addressed within this thesis some hypothetical 
possibilities based on other studies and some preliminary data from ongoing research 
will be discussed here. 
Though having definitive downstream targets such as GSH or Mn SOD largely helps 
to narrow down the search for partners or mechanisms that hTERT can employ to 
regulate the antioxidant defences, the process is still huge and, thus, a good 
understanding of the regulators of these antioxidant defences would most certainly 
facilitate this search. Literature review on mechanisms that can alter Mn SOD levels, 
GSH levels or peroxiredoxin activity proposed several options of which the most 
prominent prospect was the redox sensitive transcriptional factor NF-κB.  
NF- κB is one of the key cellular transcription factors which engages in a unique cross 
talk with ROS and has risen as a master coordinator of immunity, inflammation, 
differentiation and cell survival. NF- κB is modulated by cellular redox status and, in 
turn, it can also control cellular ROS levels via the transcription of antioxidant 
defences. In this regard, NF- κB has been shown to transcribe several antioxidant 
factors including Mn SOD and γ-glutamyl-cysteine synthetase – the rate limiting 
enzyme for GSH synthesis (Allen and Tresini, 2000; Bubici et al., 2006; Jang and 
Surh, 2004). Indeed, in a study by Jang et al, it has been shown that an increase in 




activation mediated increase in GCLC mRNA (Jang and Surh, 2004). In addition, NF-
κB has also been shown to enhance AP1 activity and the transcription of AP1’s 
downstream target genes (Fujioka et al., 2004); and one of the transcriptional targets 
of AP1 is sulfiredoxin which is involved in the regeneration of hyperoxidised Prx to 
its active form (Soriano et al., 2009; Wei et al., 2008). 
Though these studies make NF-κB an attractive target, the natural question would 
then be if there is a connection between hTERT and NF-κB that allows hTERT to 
elicit its protective effects in a NF-κB dependent manner. Addressing this issue, 
several studies have reported a physical interaction between hTERT and NF-κB 
(Akiyama et al., 2003; Kimura et al., 2004) (Akiyama et al., 2004; Ding et al., 2005). 
In that light, studies by Akiyama and group have demonstrated the direct physical 
interaction between the active phosphorylated NF-κB p65 complex and hTERT 
following tumour necrosis factor stimulation. In their reports, it was shown that the 
active NF-κB p65 complex could chaperone hTERT from the nucleus into the cytosol 
and that this nuclear import could also be inhibited by NF-κB inhibitors such as SN50 
(Akiyama et al., 2003; Akiyama et al., 2004). Given the keen association between the 
active NF-κB complex and hTERT at the nucleus, it is tempting to speculate that this 
interaction might be able to influence NF-κB's binding affinity to the DNA and 
perhaps enhance the transcription of the NF-κB driven genes. Furthermore, gene 
profiling studies performed to analyze the influence of hTERT expression in cells 
have also shown an increase in NF-κB transcription with hTERT overexpression 
(Dairkee et al., 2007). In line with these studies, our preliminary findings seem to 
suggest that in hTERT overexpressing cells there is an increased localization of p65 to 




3.6 The role of hTERT at the mitochondria 
Enhancement of antioxidant defences is just one way in which cells can regulate their 
cellular redox balance. Regulation of cellular processes to ensure optimal efficiency 
and reduce aberrant production of ROS is also critical for homeostatic redox balance. 
Cancer cells in general are metabolically active and require a high level of ATP 
supply to maintain their active biochemical functions associated with uncontrolled 
cell growth and proliferation (Lopez-Lazaro, 2008; Moreno-Sanchez et al., 2009). 
Consequently, this energy demand places a further stress on the mitochondrial 
respiration chain and is likely to contribute to increased ROS generation. Thus, 
reducing these ROS by products would certainly be of value in cancer cells.  
In that light, this study has conclusively shown that hTERT expression can lead to a 
reduction in mitochondrial O2.- levels and cellular ROS levels. Though the alterations 
in antioxidant defences might be able to account for this reduction in ROS levels, 
given the localization of hTERT to the mitochondria, it became compelling to 
investigate if the protein might be able to alter cellular redox status by engaging the 
mitochondrial machinery. 
One of the key mitochondrial proteins is cytochrome c oxidase (COX), the fourth 
complex and the rate-limiting step of the ETC, where it expends the majority of 
oxygen for reduction by Cyt. C to produce water and, as a result, generates adenosine 
triphosphate (ATP) via oxidative phosphorylation (Matoba et al., 2006; Nijtmans et 
al., 1998). Thus, COX has been considered as a reliable endogenous marker of 
oxidative metabolism in cells (Wong-Riley, 1989). Moreover, an improved COX 
activity has been often associated with lesser ROS production and a more efficient 




and, hence, less oxygen available for electrons to leak onto and produce ROS. (Papa 
and Skulachev, 1997, Skulachev, 1997).  
Given hTERT’s localization to the mitochondria (Figure 32) and its ability to 
antagonize mitochondrial ROS coupled with the functional significance of COX in 
mitochondrial respiration, here the role of hTERT in mitochondrial respiration with 
regards to COX was investigated. We present evidence from this study that cells 
overexpressing hTERT have greater basal COX activity as compared to the mock-
transfected Neo cells (Figure 33) and this can be extrapolated to an improved 
mitochondrial efficiency. As described previously, more efficient mitochondria could 
amount to lesser ROS production and could further account for the reduced O2.- levels 
in hTERT overexpressing cells. Since hTERT has been shown to localize to the inner 
and outer mitochondria, a direct interaction with COX which is an inner 
mitochondrial protein might be feasible too. Alternatively, it might be also possible 
for hTERT to modulate COX activity in an indirect manner by binding to other COX 
interacting proteins such as Bcl-2. Co- immunoprecipitation studies might be useful in 
discovering novel binding partners for hTERT at the mitochondria. Unfortunately, 
currently there are no antibodies against hTERT which can be used for 
immunoprecipitation, including that from Epitomics. Even though IP can be 
performed by pulling down the potential binding partner, the data cannot be 
reaffirmed by reverse pull down of hTERT. Thus, flag HA or myc tagged hTERT 







4. PHYSIOLOGICAL SIGNIFICANCE OF hTERT IN MODULATING 
CELLULAR REDOX BALANCE 
4.1 hTERT expression creates an intracellular environment unfavourable for 
eliciting death triggers 
Mammalian cells tightly regulate cellular ROS levels and use them as signalling 
molecules to engage a variety of cellular mechanisms which, as discussed in the 
introduction, can toggle the balance between life and death. While low levels can 
induce cell proliferation and cell growth, high levels of ROS have been implicated in 
altering the intracellular milieu inclined towards the activation of cell death 
mechanisms. Riding on the implications of altered redox balance, numerous current 
day anticancer agents such as arsenic trioxide, anthracyclines, bleomycin and 
irradiation use ROS as a signalling mechanism to engage cell death pathways 
(Pelicano et al., 2004). Indeed, the induction of ROS such as H2O2 has been identified 
as a critical mechanism to sensitize tumour cells to apoptotic stimuli by creating an 
intracellular milieu permissive for death execution. In this regard, studies have shown 
that an increase in intracellular H2O2 can lead to cytosolic acidification, which can 
subsequently engage the mitochondria mediated pathway of death signalling via Bax 
conformational change and mitochondrial translocation which triggers off 
downstream events leading to effective death execution (Ahmad et al., 2004; Clement 
et al., 1998; Hirpara et al., 2001). In addition, it has also been reported that exposure 
of tumour cells to sub-apoptotic concentrations of H2O2 can synergistically enhance 
the sensitivity of tumour cells to drug induced apoptosis (Ahmad et al., 2004; 




In this study, we have reported that cytosolic acidification induced by exposure to 
H2O2 (Figure 40) or C1 induced H2O2 (Figure 41) was significantly reduced in HT1 
cells as compared to Neo cells. In our previous findings, it has been demonstrated that 
H2O2 induced cytosolic acidification could be blocked by treatment with antioxidants 
such as catalase (Hirpara, Clement et al. 2001; Ahmad, Iskandar et al. 2004). As such, 
here it becomes apparent that the ability of hTERT to modulate cellular ROS levels 
and antagonize the increase in cellular ROS levels following exposure to H2O2 or C1 
could possibly reduce the extent of cytosolic acidification in HT1 cells and, in 
impairing the extent of acidification, we postulated the downstream events can also be 
antagonized.  
Since cytosolic acidification can induce Bax translocation to the mitochondria, the 
mitochondrial Bax levels were assessed next in Neo and HT1 cells following 
exposure to H2O2. In agreement with our postulation, more Bax was observed at the 
mitochondria in the Neo cells as compared to HT1 cells (Figure 42). The insertion of 
Bax to the outer mitochondrial membrane can lead to the disruption of the 
mitochondrial outer membrane potential subsequently leading to the loss in membrane 
potential. In addition, the increased permeabilization of the outer mitochondrial 
membrane can result in the release of apoptogenic factors such SMAC and Cyt. C 
(Orrenius, 2007; Orrenius et al., 2007).  
Here, we illustrated that the drop in mitochondrial membrane potential that ensues 
exposure to H2O2 or C1 is markedly reduced in hTERT overexpressing cells. 
Furthermore, hTERT silencing in SH-SY5Y cells was shown to enhance the drop in 
membrane potential following H2O2 treatment substantiating our findings in the 




H2O2 or C1 treated cells to study the release of apoptogenic factors demonstrated that 
the release of Cyt. C or SMAC was higher in Neo cells as compared to HT1 cells 
(Figure 42). We postulated that the impaired engagement of the cell death pathway in 
hTERT overexpressing cells due to the alteration of the cellular redox balance and 
hence, intracellular milieu would confer survival advantages on hTERT 
overexpressing cells.  
4.2 hTERT expression protects cells from apoptotic triggers 
We have clearly demonstrated in this study that hTERT expression in HeLa cells 
could confer survival advantages against ROS mediated apoptotic triggers such as 
H2O2 and C1. Assessment of cell viability following treatment showed a significant 
protection in hTERT overexpressing cells (Figures 45 and 48). Of importance, colony 
forming studies performed to illustrate the regenerative capacity of the tumour cells 
following treatment with H2O2 and C1, showed that the cells overexpressing hTERT 
were able to form a higher number of colonies, reflecting an increased propensity for 
the tumour cells expressing hTERT to recover and proliferate (Figures 47 and 49). 
This further substantiated our short term viability studies to demonstrate that hTERT 
expression can confer significant survival advantages onto the cells. Though it has 
been reported that hTERT expression can protect cells from apoptotic triggers, little 
has been unravelled on the mechanisms involved. Thus, the discovery of hTERT’s 
non canonical functions in modulating intracellular ROS levels and hence, its ability 
to create an environment that is less conducive for the engagement of cell death 
pathways, shows for a first time a ROS mediated mechanism by which hTERT 




Several studies have also previously shown that hTERT expression can shield cells 
from other cytotoxic insults such as NMDA and staurosporine. Of interest, a study by 
Dudognon et al showed that hTERT expression was able to protect NB4-LR1 cells 
from receptor mediated death signaling induced by tumour necrosis factor (TNF) and 
TNF-related apoptosis-inducing ligand (TRAIL); however, it could not protect against 
cisplatin or etoposide induced cytotoxicity (Dudognon et al., 2004). Contrary to this 
report, several studies have shown that hTERT expression is able to protect cells from 
the cytotoxic effects of cisplatin (Biroccio et al., 2003; Gorbunova et al., 2002; 
Kondo et al., 1998). In this regard, it is worth mentioning that it has been reported that 
the presence of wild type p53 has been suggested to be important for cisplatin 
cytotoxicity. In the report by Bragado et al, it was established that the apoptotic 
activity of cisplatin requires the onset of a p53-mediated p38alpha MAPK pathway 
which acts through generation of ROS (Bragado et al., 2007). Therefore, though a p53 
defective cell line can induce cytotoxic effects via other mechanisms such as DNA 
damage, its ability to elicit a death response via the induction of ROS is minimized. In 
this light, it is notable that the NB4-LR1 cell line used by Dudognon and his group 
was a p53 defective cell line. Given our results showing the significance of hTERT 
expression in diminishing ROS induced cytotoxicity, the ability of hTERT expression 
to protect some cell lines and not others could also arise from the intrinsic differences 
in the cell’s ability to engage the ROS mediated death mechanism in response to 







5. CONCLUDING REMARKS 
The selective reactivation of hTERT in cancer cells by elusive mechanisms has made 
hTERT a very attractive target in cancer research. In this regards, targeting hTERT in 
cancer cells has yielded promising results by compromising the ability of these cells 
to grow indefinitely. However, there are also drawbacks to this approach. Using anti 
hTERT strategies to target the conventional roles of telomerase maintenance and 
elongation to induce arrest and/or cell death can be a time consuming process. This 
strategy would require time for sufficient cell divisions to occur to critically shorten 
the telomeres to elicit the deleterious effects. Time however, is never in favour of 
these cancer patients. This is why telomerase inhibitors have been often presented 
along with other chemotherapeutic agents to better target these cancer cells and 
expedite the anti cancer effects. However, the recent discovery of the novel anti 
apoptotic role of hTERT, independent of its telomerase activity, has added a new 
perspective to revaluate the anti telomerase and specifically anti hTERT strategies. 
However, the mechanisms involved in eliciting this protective role have remained 
questionable.  
In this regard, this thesis provides evidence to clearly show that increased hTERT 
expression in cells can significantly antagonize the increase in cellular ROS levels in 
response to both exogenous and endogenous ROS triggers. Moreover, our 
investigations have also shed light onto the plausible mechanisms that can be 
differentially regulated with hTERT expression, thus endowing the cells with 
additional artillery to resist oxidative stress. Specifically, our findings have shown 
that hTERT expression can have significant effects on key antioxidant defences such 




addition, it has also shown a role for hTERT at the mitochondria in increasing 
mitochondrial COX activity. In unravelling the extensive influence of hTERT 
expression on cellular redox status, this study has also outlined a mechanism by which 
hTERT overexpressing cells can safeguard their intracellular milieu from the 
detrimental effects of ROS, such as cytosolic acidification and the subsequent 
mitochondrial engagement, thus conferring significant protection from cell death.  
Taken together, this study has, for a first time, firmly established the cross talk 
between hTERT and ROS and demonstrates how hTERT expression can confer 
survival advantages onto the cells by twigging the cellular capacity to manage 
oxidative stress. These findings open a promising field of investigation on the anti-
apoptotic role of hTERT that arises from its ability to manipulate cellular redox 
balance. At the present time, it is difficult to hazard an accurate conjecture on the 
exact mechanisms by which hTERT might be regulating the specific antioxidant 
defences or increasing COX activity, but the postulations mapped out in these thesis 




 Figure 48: Mechanism by which hTERT can confer protection against oxidative 
death triggers.  hTERT is usually localized at the nucleus. There, its interaction with 
transcription factors (TF) such as NF-κB may offer an explanation to the enhanced 
antioxidant defences (e.g. GSH, Mn SOD, Prx activity) and lowered cellular ROS 
levels that is observed with hTERT expression. Exogenous reactive oxygen species 
(ROS) have been shown to trigger nuclear export of hTERT. At the cytosol, hTERT 
can interact with mitochondrial import proteins (IP) such as Tom 20 that facilitates its 
import into the mitochondria. Once at the mitochondria, hTERT may enhance 
mitochondrial activity, hence reducing mitochondrial ROS production. The exposure 
to exogenous and endogenous ROS triggers can induce cytosolic acidification that can 
subsequently induce Bax translocation to the mitochondria. Insertion of Bax into the 
mitochondria can lead to the dissipation of mitochondrial membrane potential (m) 
and the release of cytochrome c (Cyt. C), SMAC and other pro-apoptogenic factors 
(PA) culminating in cell death. 
 
Given that ROS mediated apoptosis can be suppressed when hTERT is overexpressed, 
translating these findings to a physiological model, cancer cells with intrinsically 
higher levels of hTERT might be less responsive to chemotherapeutic regiments that 
function via ROS mediated mechanisms to elicit death responses. Hence, under such 




antioxidant defences or using drugs that do not depend on a ROS mediated 
mechanism of action might help to sensitize these cells better to death triggers. Thus, 
the observations made in this report along with that presented by other studies 
demonstrate that hTERT may have broad biological consequences in addition to its 
essential function for telomere elongation and maintenance. This clearly illustrates the 
paradigm shift in telomerase biology and the need for new pharmacological 
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